[
  {
    "sentence": "Current or prior smoking (p = 0.028), poor ECOG performance (ECOG 3–4, p=0.001), and active cancer status (p=0.024) (Fig. 1) were all associated with increased COVID-19 mortality.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Similar results were observed in time-to-event analyses using Kaplan Meier methods (Fig. 2a, median overall survival (mOS) not reached for patients with solid cancers vs 47 days for patients with hematologic cancers, p-value=0.030) and Cox regression models (Table 2, HR 2.56, 95% CI 1.19–5.54, p=0.017).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Moreover, patients with hematologic cancers had higher levels of some inflammatory markers on admission laboratory testing, including ferritin, IL-6, and LDH (Fig. 2b, Extended Data Fig. 1a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Both hematologic and solid cancer patients had prolonged viral clearance, with some greater than 60 days (Extended Data Figure 1c,d, Supplemental Table 3).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel c",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Patients with active cancer were older and predominantly female; both groups had a similar timeframe of symptom onset and disease severity (Fig. 3a, Supplemental Table 4).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel a",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "However, cancer patients had a higher all-cause mortality (36.4% versus 11.1%, Fig. 3a), consistent with our COPE cohort and other reported cohorts21, 24,27,28.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel a",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Cancer patients had significantly decreased SARS-CoV-2-specific IgG and IgM antibodies compared to non-cancer patients (Extended Data Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This was largely due to hematologic cancer patients, the majority (6/7) of whom had IgM and IgG levels below the cutoff of positivity of 0.48 arbitrary units (Fig. 3b, Extended Data Fig. 2b), while those with solid cancers had IgG and IgM antibody responses that were more comparable to patients without cancer (Fig. 3b).T cell-depleted phenotype associated with COVID-19 mortality\nPatients who recover from COVID-19 also exhibit SARS-CoV-2-specific CD4 and CD8 T cell responses43,44.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "UMAP (Uniform Manifold Approximation and Projection) representation of 27-parameter flow cytometry data highlighted discrete islands of CD4 and CD8 T cells, and CD19+ B cells (Fig. 3c and Extended Data Fig. 3a).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel a",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Clustering on EMD values identified 5 clusters of patients with similar lymphocyte profiles (Fig. 3c).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Differences between these clusters of patients were driven by both the distribution (Fig. 3d and Extended Data Fig. 3b) and phenotype (Fig. 3e) of CD4, CD8, and B cells.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel d",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "EMD cluster 1 was defined by depleted CD4 and B cells, increased CD8 T cells, and increased activation and effector markers, including PD-1, CX3CR1, Ki67, and HLA-DR (Fig. 3 d,e and Extended Data Fig. 3b).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In contrast, EMD cluster 4 was defined by robust CCR7+CD27+ memory CD4 T cell responses and heterogenous B cell responses; EMD cluster 2 had the most balanced responses, with CD4, CD8, and B cells represented (Fig. 3d,e and Extended Data Fig. 3b).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel d",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "EMD cluster 5 patients with depleted T cells had the highest mortality and disease severity, despite generating SARS-CoV-2-specific IgM and IgG antibodies (Fig. 3f, Extended Data Fig. 5d).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel f",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel d",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "In contrast, EMD clusters 2 and 4, with robust CD4 and/or CD8 T cell responses, had the lowest mortality and a low disease severity (Fig. 3f, Extended Data Fig. 5d).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel f",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel d",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Four out of the 6 solid cancer patients were in EMD cluster 2, with a balanced immune phenotype (Fig. 3e).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Indeed, UMAP projections showed that while solid cancer patients had an immune landscape similar to non-cancer patients, the two hematologic cancer patients demonstrated loss of islands associated with CD4 and B cells (Fig. 3g).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel g",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel g",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel g",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "COVID-19 patients with hematologic cancers had a significantly lower frequency of CD4 and B cells compared to solid cancer patients, non-cancer patients, and healthy donors without COVID-19 (Fig. 3h).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel h",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel h",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel h",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Although limited by sample size, patients with hematologic cancers had low circulating Tfh (PD1+ CXCR5+) and plasmablast responses (CD19+CD27hiCD38hi) and decreased CD138 expression (Extended Data Fig. 4a).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "UMAP clearly separated CX3CR1 and Tbet expressing effector cells from memory CD8 T cells expressing CD27 and TCF-1 (Extended Data Fig. 4b and Fig. 3i).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel b",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel i",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Activated cells, characterized by high HLA-DR, CD38, and Ki67 expression, were identified in clusters 3, 4, and 5 (Extended Data Fig. 4c).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel c",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "CD8 T cell subsets including central memory, effector memory, transitional memory and TEMRA, were similar between patients with and without cancer (Extended Data Fig. 4d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel d",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "However, UMAP representation of non-naïve CD8 data demonstrated preferential enrichment of cells expressing HLA-DR and CD38 in cancer patients compared to non-cancer patients (Fig. 3j).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel j",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel j",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel j",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Indeed, cancer patients had higher frequencies of activated HLA-DR, CD38, and Ki67-expressing FlowSOM clusters (clusters 3, 4, and 5) compared to non-cancer patients and healthy donors (Fig. 3k and Extended Data Fig. 4e).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel k",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel e",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "When stratified by cancer type, the increased HLA-DR and CD38 expression was restricted to the patients with hematologic cancers; patients with solid cancers and those without cancer had comparable levels of activation (Fig. 3l).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel l",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel l",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel l",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The median age of the MSKCC cohort was 65 years, and in contrast to the MESSI cohort at Penn, 81% of the cohort was white (Fig. 4a, Supplemental Table 7,8).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Consistent with the Penn COPE and MESSI cohorts, patients with hematologic cancers did poorly, with a mortality rate of 44.4% (Fig. 4a, Supplemental Table 7).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In the MSKCC cohort, both CD4 and CD8 T cells were significantly decreased in patients with active solid and hematologic cancers, compared with patients in clinical remission (Extended Data Fig. 5a).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel a",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Moreover, despite the fact that a substantial number of patients with hematologic cancers from the MSKCC cohort received convalescent plasma (Supplemental Table 7), they had a significant defect in SARS-CoV-2-specific IgG and IgM responses as compared to solid cancers (Extended Data Fig. 5b).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel b",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "This was independent of disease severity and viral load (Extended Data Fig. 5c,d).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel c",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.EMD and clustering of flow cytometry data from 20 solid cancer, 31 hematologic cancer, and 6 remission patients identified 4 immune phenotypes (Fig. 4b,c and Extended Data Fig. 6a,b) that corresponded to the immune phenotypes 1,2,4, and 5 identified in the Penn-MESSI cohort (Fig. 3c,d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel b",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel a",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Consistent with the Penn data, MSKCC EMD cluster 5, with depleted of CD4 and CD8 T cells and preserved B cells, had the highest mortality of 71%, and was associated with a high disease severity and viral load (Fig 4d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel d",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel d",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel d",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Solid cancer patients in the MSKCC cohort were present in all 4 clusters, with a majority in cluster 4, while hematologic cancer patients were predominantly in clusters 1 and 4 and absent from cluster 2 (Extended Data Figure 7a and b).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel a",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Hematologic cancer patients with phenotype 4 had a mortality of 62% versus 9% in patients with solid cancers (Extended Data Fig. 7c), with a corresponding higher viral load (Extended Data Fig. 7d).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel c",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel d",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Immune phenotype 4 was characterized by robust CD4 responses and decreased, but still present, CD8 responses (Extended Data Fig 6b).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel b",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Within immune phenotype 4, patients with solid and hematologic cancers had similar CD4 and CD8 T cell counts (Extended Data Figure 7e).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel e",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "However, patients with hematologic cancers had near-complete abrogation of B cells (phenotype 4A) that corresponded with a mortality rate of 62% (Extended Fig 7c and f).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel c",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "In contrast, patients with solid cancers had intact B cells counts (phenotype 4B) with a mortality of 9% (Extended Data Fig 7c and f).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel c",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Anti-CD20 therapy (αCD20) with rituximab or obinutuzumab-containing regimens depleted circulating B cells and significantly impaired SARS-CoV-2-specific IgG and IgM responses (Fig. 4e, Extended Data Fig. 8a). αCD20 was not associated with quantitative changes in CD4 and CD8 T cells.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel e",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel a",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "However, patients treated with anti-CD20 therapy exhibited significant reductions in CD4 and CD8 naïve and memory T cells, with a relative skewing towards effector differentiation and an activated HLA-DR+CD38+ phenotype (Extended Data Fig. 8b,c).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel b",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "These changes were not seen in αCD20-treated hematologic patients without COVID-19 (Extended Data Fig. 8d,e).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel d",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Importantly, despite the loss of B cells and humoral immunity, αCD20 therapy was not associated with increased mortality, disease severity, or viral load when compared to chemotherapy or observation (Extended Data Fig. 9a).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel a",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Patients treated with αCD20 therapy were restricted to immune phenotypes 1 and 4, characterized by depleted B cells (Extended Data Fig. 9b).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel b",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "However, phenotype 1, characterized by preserved CD8 T cells, was associated with a lower mortality (Extended Data Fig. 9c).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel c",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Indeed, αCD20 treated patients who survived their COVID-19 hospitalization had higher CD8 T cell counts (Fig 4f), and lower viral load (Extended Data Fig. 9d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel f",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel d",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel f",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel f",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "We extended these analyses to other patients with hematologic cancers, including those on chemotherapy who also had quantitative (Extended Data Fig. 8a), and possibly qualitative B cell defects.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel a",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Hematologic cancer patients who survived had higher CD8 T cell count (Fig. 4g), which was not observed in solid cancer patients (Extended Data Fig. 9e).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel g",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel e",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel g",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel g",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Conversely, CD4 T cell counts were not associated with mortality, and higher B cell counts were associated with increased mortality (Extended Data Fig. 9e, Fig 4g).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel e",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel g",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Classification and Regression Tree Analysis (CART) identified a CD8 T cell level that was predictive of survival after COVID-19 in patients with hematologic cancers (Fig. 4h).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel h",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel h",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel h",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Finally, to assess the antigen-specificity of T cell responses in SARS-CoV-2 infected cancer patients, we stimulated PBMC from 13 hematologic cancer patients and 10 solid cancer patients using MHC-I and MHC-II restricted SARS-CoV-2 and EBV peptide pools and measured IFN-γ and IL-2 responses using ELISpot (Extended Data Figure 10a).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "Panel a",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "After background (no-peptide) subtraction, 10 out of 13 (77%) of hematologic cancer patients had SARS-CoV-2- specific IL-2 and/or IFN-γ responses (Figure 4i), including 8 out of 8 (100%) of patients treated with αCD20 (Figure 4j, Extended Data Fig 10b).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel i",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel j",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel b",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel i",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In general, these SARS-CoV-2-specific responses were greater in magnitude than EBV-specific responses (Figure 4i), and hematologic cancer patients had greater SARS-CoV-2 antigen-specific T cell responses than solid cancer patients (Extended Data Fig 10c).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel i",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel c",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel i",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Moreover, in hematologic cancer patients who recovered from COVID-19, SARS-CoV-2-specific IFN-γ responses correlated with the frequency of HLA-DR+CD38+ CD8 T cells (Fig 4k), but not with HLA-DR+CD38+ CD4 T cells (Extended Data 10d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel k",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel k",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel k",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "This correlation was not seen in patients who died (Extended Data Fig 10e).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "Panel e",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Results are expressed in Spot Forming Units (SFU) per 10^6 PBMCs.Extended Data\nExtended Data Fig. 1 |.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Repeat SARS-CoV-2 RT-PCR testing results (c) from first positive test to last performed test and (d) from first positive test to last positive test. (All) Significance determined by two-sided Mann Whitney test.Extended Data Fig. 2 |.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 3 |.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\n(a) UMAP projections of lymphocytes with indicated protein expression. (b) Frequencies of CD19+, CD3+, CD3+CD8+, and CD3+CD4+ cells of patients in each EMD cluster (Cluster 1 n=7; Cluster 2 n=16; Cluster 3 n=6; Cluster 4 n=10; Cluster 5 n=5). (All) Median and 95% CI shown.Extended Data Fig. 4 |.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 5 |.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 6 |.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\n(a) UMAP projections of lymphocytes with indicated protein expression. (b) Absolute counts of CD19+, CD3+, CD3+CD8+, and CD3+CD4+ cells of patients in each EMD cluster (Cluster 1 n=18; Cluster 2 n=6; Cluster 4 n=26; Cluster 5 n=7). (All) Median and 95% CI shown.Extended Data Fig. 7 |.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 8 |.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 9 |.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 10 |.",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Current or prior smoking (p = 0.028), poor ECOG performance (ECOG 3–4, p=0.001), and active cancer status (p=0.024) (Fig. 1) were all associated with increased COVID-19 mortality.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Similar results were observed in time-to-event analyses using Kaplan Meier methods (Fig. 2a, median overall survival (mOS) not reached for patients with solid cancers vs 47 days for patients with hematologic cancers, p-value=0.030) and Cox regression models (Table 2, HR 2.56, 95% CI 1.19–5.54, p=0.017).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Moreover, patients with hematologic cancers had higher levels of some inflammatory markers on admission laboratory testing, including ferritin, IL-6, and LDH (Fig. 2b, Extended Data Fig. 1a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Both hematologic and solid cancer patients had prolonged viral clearance, with some greater than 60 days (Extended Data Figure 1c,d, Supplemental Table 3).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel c",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Patients with active cancer were older and predominantly female; both groups had a similar timeframe of symptom onset and disease severity (Fig. 3a, Supplemental Table 4).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel a",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "However, cancer patients had a higher all-cause mortality (36.4% versus 11.1%, Fig. 3a), consistent with our COPE cohort and other reported cohorts21, 24,27,28.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel a",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Cancer patients had significantly decreased SARS-CoV-2-specific IgG and IgM antibodies compared to non-cancer patients (Extended Data Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This was largely due to hematologic cancer patients, the majority (6/7) of whom had IgM and IgG levels below the cutoff of positivity of 0.48 arbitrary units (Fig. 3b, Extended Data Fig. 2b), while those with solid cancers had IgG and IgM antibody responses that were more comparable to patients without cancer (Fig. 3b).T cell-depleted phenotype associated with COVID-19 mortality\nPatients who recover from COVID-19 also exhibit SARS-CoV-2-specific CD4 and CD8 T cell responses43,44.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "UMAP (Uniform Manifold Approximation and Projection) representation of 27-parameter flow cytometry data highlighted discrete islands of CD4 and CD8 T cells, and CD19+ B cells (Fig. 3c and Extended Data Fig. 3a).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel a",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Clustering on EMD values identified 5 clusters of patients with similar lymphocyte profiles (Fig. 3c).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Differences between these clusters of patients were driven by both the distribution (Fig. 3d and Extended Data Fig. 3b) and phenotype (Fig. 3e) of CD4, CD8, and B cells.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel d",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "EMD cluster 1 was defined by depleted CD4 and B cells, increased CD8 T cells, and increased activation and effector markers, including PD-1, CX3CR1, Ki67, and HLA-DR (Fig. 3 d,e and Extended Data Fig. 3b).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In contrast, EMD cluster 4 was defined by robust CCR7+CD27+ memory CD4 T cell responses and heterogenous B cell responses; EMD cluster 2 had the most balanced responses, with CD4, CD8, and B cells represented (Fig. 3d,e and Extended Data Fig. 3b).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel d",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "EMD cluster 5 patients with depleted T cells had the highest mortality and disease severity, despite generating SARS-CoV-2-specific IgM and IgG antibodies (Fig. 3f, Extended Data Fig. 5d).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel f",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel d",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "In contrast, EMD clusters 2 and 4, with robust CD4 and/or CD8 T cell responses, had the lowest mortality and a low disease severity (Fig. 3f, Extended Data Fig. 5d).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel f",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel d",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Four out of the 6 solid cancer patients were in EMD cluster 2, with a balanced immune phenotype (Fig. 3e).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Indeed, UMAP projections showed that while solid cancer patients had an immune landscape similar to non-cancer patients, the two hematologic cancer patients demonstrated loss of islands associated with CD4 and B cells (Fig. 3g).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel g",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel g",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel g",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "COVID-19 patients with hematologic cancers had a significantly lower frequency of CD4 and B cells compared to solid cancer patients, non-cancer patients, and healthy donors without COVID-19 (Fig. 3h).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel h",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel h",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel h",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Although limited by sample size, patients with hematologic cancers had low circulating Tfh (PD1+ CXCR5+) and plasmablast responses (CD19+CD27hiCD38hi) and decreased CD138 expression (Extended Data Fig. 4a).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "UMAP clearly separated CX3CR1 and Tbet expressing effector cells from memory CD8 T cells expressing CD27 and TCF-1 (Extended Data Fig. 4b and Fig. 3i).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel b",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel i",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Activated cells, characterized by high HLA-DR, CD38, and Ki67 expression, were identified in clusters 3, 4, and 5 (Extended Data Fig. 4c).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel c",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "CD8 T cell subsets including central memory, effector memory, transitional memory and TEMRA, were similar between patients with and without cancer (Extended Data Fig. 4d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel d",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "However, UMAP representation of non-naïve CD8 data demonstrated preferential enrichment of cells expressing HLA-DR and CD38 in cancer patients compared to non-cancer patients (Fig. 3j).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel j",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel j",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel j",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Indeed, cancer patients had higher frequencies of activated HLA-DR, CD38, and Ki67-expressing FlowSOM clusters (clusters 3, 4, and 5) compared to non-cancer patients and healthy donors (Fig. 3k and Extended Data Fig. 4e).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel k",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel e",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "When stratified by cancer type, the increased HLA-DR and CD38 expression was restricted to the patients with hematologic cancers; patients with solid cancers and those without cancer had comparable levels of activation (Fig. 3l).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel l",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel l",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel l",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The median age of the MSKCC cohort was 65 years, and in contrast to the MESSI cohort at Penn, 81% of the cohort was white (Fig. 4a, Supplemental Table 7,8).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Consistent with the Penn COPE and MESSI cohorts, patients with hematologic cancers did poorly, with a mortality rate of 44.4% (Fig. 4a, Supplemental Table 7).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In the MSKCC cohort, both CD4 and CD8 T cells were significantly decreased in patients with active solid and hematologic cancers, compared with patients in clinical remission (Extended Data Fig. 5a).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel a",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Moreover, despite the fact that a substantial number of patients with hematologic cancers from the MSKCC cohort received convalescent plasma (Supplemental Table 7), they had a significant defect in SARS-CoV-2-specific IgG and IgM responses as compared to solid cancers (Extended Data Fig. 5b).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel b",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "This was independent of disease severity and viral load (Extended Data Fig. 5c,d).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel c",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.EMD and clustering of flow cytometry data from 20 solid cancer, 31 hematologic cancer, and 6 remission patients identified 4 immune phenotypes (Fig. 4b,c and Extended Data Fig. 6a,b) that corresponded to the immune phenotypes 1,2,4, and 5 identified in the Penn-MESSI cohort (Fig. 3c,d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel b",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel a",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Consistent with the Penn data, MSKCC EMD cluster 5, with depleted of CD4 and CD8 T cells and preserved B cells, had the highest mortality of 71%, and was associated with a high disease severity and viral load (Fig 4d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel d",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel d",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel d",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Solid cancer patients in the MSKCC cohort were present in all 4 clusters, with a majority in cluster 4, while hematologic cancer patients were predominantly in clusters 1 and 4 and absent from cluster 2 (Extended Data Figure 7a and b).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel a",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Hematologic cancer patients with phenotype 4 had a mortality of 62% versus 9% in patients with solid cancers (Extended Data Fig. 7c), with a corresponding higher viral load (Extended Data Fig. 7d).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel c",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel d",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Immune phenotype 4 was characterized by robust CD4 responses and decreased, but still present, CD8 responses (Extended Data Fig 6b).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel b",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Within immune phenotype 4, patients with solid and hematologic cancers had similar CD4 and CD8 T cell counts (Extended Data Figure 7e).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel e",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "However, patients with hematologic cancers had near-complete abrogation of B cells (phenotype 4A) that corresponded with a mortality rate of 62% (Extended Fig 7c and f).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel c",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "In contrast, patients with solid cancers had intact B cells counts (phenotype 4B) with a mortality of 9% (Extended Data Fig 7c and f).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel c",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Anti-CD20 therapy (αCD20) with rituximab or obinutuzumab-containing regimens depleted circulating B cells and significantly impaired SARS-CoV-2-specific IgG and IgM responses (Fig. 4e, Extended Data Fig. 8a). αCD20 was not associated with quantitative changes in CD4 and CD8 T cells.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel e",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel a",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "However, patients treated with anti-CD20 therapy exhibited significant reductions in CD4 and CD8 naïve and memory T cells, with a relative skewing towards effector differentiation and an activated HLA-DR+CD38+ phenotype (Extended Data Fig. 8b,c).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel b",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "These changes were not seen in αCD20-treated hematologic patients without COVID-19 (Extended Data Fig. 8d,e).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel d",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Importantly, despite the loss of B cells and humoral immunity, αCD20 therapy was not associated with increased mortality, disease severity, or viral load when compared to chemotherapy or observation (Extended Data Fig. 9a).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel a",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Patients treated with αCD20 therapy were restricted to immune phenotypes 1 and 4, characterized by depleted B cells (Extended Data Fig. 9b).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel b",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "However, phenotype 1, characterized by preserved CD8 T cells, was associated with a lower mortality (Extended Data Fig. 9c).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel c",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Indeed, αCD20 treated patients who survived their COVID-19 hospitalization had higher CD8 T cell counts (Fig 4f), and lower viral load (Extended Data Fig. 9d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel f",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel d",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel f",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel f",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "We extended these analyses to other patients with hematologic cancers, including those on chemotherapy who also had quantitative (Extended Data Fig. 8a), and possibly qualitative B cell defects.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel a",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Hematologic cancer patients who survived had higher CD8 T cell count (Fig. 4g), which was not observed in solid cancer patients (Extended Data Fig. 9e).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel g",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel e",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel g",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel g",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Conversely, CD4 T cell counts were not associated with mortality, and higher B cell counts were associated with increased mortality (Extended Data Fig. 9e, Fig 4g).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel e",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel g",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Classification and Regression Tree Analysis (CART) identified a CD8 T cell level that was predictive of survival after COVID-19 in patients with hematologic cancers (Fig. 4h).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel h",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel h",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel h",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Finally, to assess the antigen-specificity of T cell responses in SARS-CoV-2 infected cancer patients, we stimulated PBMC from 13 hematologic cancer patients and 10 solid cancer patients using MHC-I and MHC-II restricted SARS-CoV-2 and EBV peptide pools and measured IFN-γ and IL-2 responses using ELISpot (Extended Data Figure 10a).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "Panel a",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "After background (no-peptide) subtraction, 10 out of 13 (77%) of hematologic cancer patients had SARS-CoV-2- specific IL-2 and/or IFN-γ responses (Figure 4i), including 8 out of 8 (100%) of patients treated with αCD20 (Figure 4j, Extended Data Fig 10b).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel i",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel j",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel b",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel i",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In general, these SARS-CoV-2-specific responses were greater in magnitude than EBV-specific responses (Figure 4i), and hematologic cancer patients had greater SARS-CoV-2 antigen-specific T cell responses than solid cancer patients (Extended Data Fig 10c).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel i",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel c",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel i",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Moreover, in hematologic cancer patients who recovered from COVID-19, SARS-CoV-2-specific IFN-γ responses correlated with the frequency of HLA-DR+CD38+ CD8 T cells (Fig 4k), but not with HLA-DR+CD38+ CD4 T cells (Extended Data 10d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel k",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel k",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel k",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "This correlation was not seen in patients who died (Extended Data Fig 10e).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "Panel e",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Results are expressed in Spot Forming Units (SFU) per 10^6 PBMCs.Extended Data\nExtended Data Fig. 1 |.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Repeat SARS-CoV-2 RT-PCR testing results (c) from first positive test to last performed test and (d) from first positive test to last positive test. (All) Significance determined by two-sided Mann Whitney test.Extended Data Fig. 2 |.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 3 |.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\n(a) UMAP projections of lymphocytes with indicated protein expression. (b) Frequencies of CD19+, CD3+, CD3+CD8+, and CD3+CD4+ cells of patients in each EMD cluster (Cluster 1 n=7; Cluster 2 n=16; Cluster 3 n=6; Cluster 4 n=10; Cluster 5 n=5). (All) Median and 95% CI shown.Extended Data Fig. 4 |.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 5 |.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 6 |.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\n(a) UMAP projections of lymphocytes with indicated protein expression. (b) Absolute counts of CD19+, CD3+, CD3+CD8+, and CD3+CD4+ cells of patients in each EMD cluster (Cluster 1 n=18; Cluster 2 n=6; Cluster 4 n=26; Cluster 5 n=7). (All) Median and 95% CI shown.Extended Data Fig. 7 |.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 8 |.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 9 |.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 10 |.",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Current or prior smoking (p = 0.028), poor ECOG performance (ECOG 3–4, p=0.001), and active cancer status (p=0.024) (Fig. 1) were all associated with increased COVID-19 mortality.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Similar results were observed in time-to-event analyses using Kaplan Meier methods (Fig. 2a, median overall survival (mOS) not reached for patients with solid cancers vs 47 days for patients with hematologic cancers, p-value=0.030) and Cox regression models (Table 2, HR 2.56, 95% CI 1.19–5.54, p=0.017).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Moreover, patients with hematologic cancers had higher levels of some inflammatory markers on admission laboratory testing, including ferritin, IL-6, and LDH (Fig. 2b, Extended Data Fig. 1a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Both hematologic and solid cancer patients had prolonged viral clearance, with some greater than 60 days (Extended Data Figure 1c,d, Supplemental Table 3).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel c",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Patients with active cancer were older and predominantly female; both groups had a similar timeframe of symptom onset and disease severity (Fig. 3a, Supplemental Table 4).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel a",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "However, cancer patients had a higher all-cause mortality (36.4% versus 11.1%, Fig. 3a), consistent with our COPE cohort and other reported cohorts21, 24,27,28.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel a",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Cancer patients had significantly decreased SARS-CoV-2-specific IgG and IgM antibodies compared to non-cancer patients (Extended Data Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This was largely due to hematologic cancer patients, the majority (6/7) of whom had IgM and IgG levels below the cutoff of positivity of 0.48 arbitrary units (Fig. 3b, Extended Data Fig. 2b), while those with solid cancers had IgG and IgM antibody responses that were more comparable to patients without cancer (Fig. 3b).T cell-depleted phenotype associated with COVID-19 mortality\nPatients who recover from COVID-19 also exhibit SARS-CoV-2-specific CD4 and CD8 T cell responses43,44.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "UMAP (Uniform Manifold Approximation and Projection) representation of 27-parameter flow cytometry data highlighted discrete islands of CD4 and CD8 T cells, and CD19+ B cells (Fig. 3c and Extended Data Fig. 3a).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel a",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Clustering on EMD values identified 5 clusters of patients with similar lymphocyte profiles (Fig. 3c).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Differences between these clusters of patients were driven by both the distribution (Fig. 3d and Extended Data Fig. 3b) and phenotype (Fig. 3e) of CD4, CD8, and B cells.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel d",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "EMD cluster 1 was defined by depleted CD4 and B cells, increased CD8 T cells, and increased activation and effector markers, including PD-1, CX3CR1, Ki67, and HLA-DR (Fig. 3 d,e and Extended Data Fig. 3b).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In contrast, EMD cluster 4 was defined by robust CCR7+CD27+ memory CD4 T cell responses and heterogenous B cell responses; EMD cluster 2 had the most balanced responses, with CD4, CD8, and B cells represented (Fig. 3d,e and Extended Data Fig. 3b).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel d",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "EMD cluster 5 patients with depleted T cells had the highest mortality and disease severity, despite generating SARS-CoV-2-specific IgM and IgG antibodies (Fig. 3f, Extended Data Fig. 5d).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel f",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel d",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "In contrast, EMD clusters 2 and 4, with robust CD4 and/or CD8 T cell responses, had the lowest mortality and a low disease severity (Fig. 3f, Extended Data Fig. 5d).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel f",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel d",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Four out of the 6 solid cancer patients were in EMD cluster 2, with a balanced immune phenotype (Fig. 3e).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Indeed, UMAP projections showed that while solid cancer patients had an immune landscape similar to non-cancer patients, the two hematologic cancer patients demonstrated loss of islands associated with CD4 and B cells (Fig. 3g).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel g",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel g",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel g",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "COVID-19 patients with hematologic cancers had a significantly lower frequency of CD4 and B cells compared to solid cancer patients, non-cancer patients, and healthy donors without COVID-19 (Fig. 3h).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel h",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel h",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel h",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Although limited by sample size, patients with hematologic cancers had low circulating Tfh (PD1+ CXCR5+) and plasmablast responses (CD19+CD27hiCD38hi) and decreased CD138 expression (Extended Data Fig. 4a).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "UMAP clearly separated CX3CR1 and Tbet expressing effector cells from memory CD8 T cells expressing CD27 and TCF-1 (Extended Data Fig. 4b and Fig. 3i).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel b",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel i",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Activated cells, characterized by high HLA-DR, CD38, and Ki67 expression, were identified in clusters 3, 4, and 5 (Extended Data Fig. 4c).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel c",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "CD8 T cell subsets including central memory, effector memory, transitional memory and TEMRA, were similar between patients with and without cancer (Extended Data Fig. 4d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel d",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "However, UMAP representation of non-naïve CD8 data demonstrated preferential enrichment of cells expressing HLA-DR and CD38 in cancer patients compared to non-cancer patients (Fig. 3j).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel j",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel j",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel j",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Indeed, cancer patients had higher frequencies of activated HLA-DR, CD38, and Ki67-expressing FlowSOM clusters (clusters 3, 4, and 5) compared to non-cancer patients and healthy donors (Fig. 3k and Extended Data Fig. 4e).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel k",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel e",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "When stratified by cancer type, the increased HLA-DR and CD38 expression was restricted to the patients with hematologic cancers; patients with solid cancers and those without cancer had comparable levels of activation (Fig. 3l).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel l",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel l",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel l",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The median age of the MSKCC cohort was 65 years, and in contrast to the MESSI cohort at Penn, 81% of the cohort was white (Fig. 4a, Supplemental Table 7,8).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Consistent with the Penn COPE and MESSI cohorts, patients with hematologic cancers did poorly, with a mortality rate of 44.4% (Fig. 4a, Supplemental Table 7).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In the MSKCC cohort, both CD4 and CD8 T cells were significantly decreased in patients with active solid and hematologic cancers, compared with patients in clinical remission (Extended Data Fig. 5a).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel a",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Moreover, despite the fact that a substantial number of patients with hematologic cancers from the MSKCC cohort received convalescent plasma (Supplemental Table 7), they had a significant defect in SARS-CoV-2-specific IgG and IgM responses as compared to solid cancers (Extended Data Fig. 5b).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel b",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "This was independent of disease severity and viral load (Extended Data Fig. 5c,d).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel c",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.EMD and clustering of flow cytometry data from 20 solid cancer, 31 hematologic cancer, and 6 remission patients identified 4 immune phenotypes (Fig. 4b,c and Extended Data Fig. 6a,b) that corresponded to the immune phenotypes 1,2,4, and 5 identified in the Penn-MESSI cohort (Fig. 3c,d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel b",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel a",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Consistent with the Penn data, MSKCC EMD cluster 5, with depleted of CD4 and CD8 T cells and preserved B cells, had the highest mortality of 71%, and was associated with a high disease severity and viral load (Fig 4d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel d",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel d",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel d",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Solid cancer patients in the MSKCC cohort were present in all 4 clusters, with a majority in cluster 4, while hematologic cancer patients were predominantly in clusters 1 and 4 and absent from cluster 2 (Extended Data Figure 7a and b).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel a",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Hematologic cancer patients with phenotype 4 had a mortality of 62% versus 9% in patients with solid cancers (Extended Data Fig. 7c), with a corresponding higher viral load (Extended Data Fig. 7d).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel c",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel d",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Immune phenotype 4 was characterized by robust CD4 responses and decreased, but still present, CD8 responses (Extended Data Fig 6b).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel b",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Within immune phenotype 4, patients with solid and hematologic cancers had similar CD4 and CD8 T cell counts (Extended Data Figure 7e).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel e",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "However, patients with hematologic cancers had near-complete abrogation of B cells (phenotype 4A) that corresponded with a mortality rate of 62% (Extended Fig 7c and f).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel c",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "In contrast, patients with solid cancers had intact B cells counts (phenotype 4B) with a mortality of 9% (Extended Data Fig 7c and f).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel c",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Anti-CD20 therapy (αCD20) with rituximab or obinutuzumab-containing regimens depleted circulating B cells and significantly impaired SARS-CoV-2-specific IgG and IgM responses (Fig. 4e, Extended Data Fig. 8a). αCD20 was not associated with quantitative changes in CD4 and CD8 T cells.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel e",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel a",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "However, patients treated with anti-CD20 therapy exhibited significant reductions in CD4 and CD8 naïve and memory T cells, with a relative skewing towards effector differentiation and an activated HLA-DR+CD38+ phenotype (Extended Data Fig. 8b,c).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel b",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "These changes were not seen in αCD20-treated hematologic patients without COVID-19 (Extended Data Fig. 8d,e).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel d",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Importantly, despite the loss of B cells and humoral immunity, αCD20 therapy was not associated with increased mortality, disease severity, or viral load when compared to chemotherapy or observation (Extended Data Fig. 9a).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel a",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Patients treated with αCD20 therapy were restricted to immune phenotypes 1 and 4, characterized by depleted B cells (Extended Data Fig. 9b).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel b",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "However, phenotype 1, characterized by preserved CD8 T cells, was associated with a lower mortality (Extended Data Fig. 9c).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel c",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Indeed, αCD20 treated patients who survived their COVID-19 hospitalization had higher CD8 T cell counts (Fig 4f), and lower viral load (Extended Data Fig. 9d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel f",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel d",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel f",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel f",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "We extended these analyses to other patients with hematologic cancers, including those on chemotherapy who also had quantitative (Extended Data Fig. 8a), and possibly qualitative B cell defects.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel a",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Hematologic cancer patients who survived had higher CD8 T cell count (Fig. 4g), which was not observed in solid cancer patients (Extended Data Fig. 9e).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel g",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel e",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel g",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel g",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Conversely, CD4 T cell counts were not associated with mortality, and higher B cell counts were associated with increased mortality (Extended Data Fig. 9e, Fig 4g).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel e",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel g",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Classification and Regression Tree Analysis (CART) identified a CD8 T cell level that was predictive of survival after COVID-19 in patients with hematologic cancers (Fig. 4h).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel h",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel h",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel h",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Finally, to assess the antigen-specificity of T cell responses in SARS-CoV-2 infected cancer patients, we stimulated PBMC from 13 hematologic cancer patients and 10 solid cancer patients using MHC-I and MHC-II restricted SARS-CoV-2 and EBV peptide pools and measured IFN-γ and IL-2 responses using ELISpot (Extended Data Figure 10a).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "Panel a",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "After background (no-peptide) subtraction, 10 out of 13 (77%) of hematologic cancer patients had SARS-CoV-2- specific IL-2 and/or IFN-γ responses (Figure 4i), including 8 out of 8 (100%) of patients treated with αCD20 (Figure 4j, Extended Data Fig 10b).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel i",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel j",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel b",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel i",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In general, these SARS-CoV-2-specific responses were greater in magnitude than EBV-specific responses (Figure 4i), and hematologic cancer patients had greater SARS-CoV-2 antigen-specific T cell responses than solid cancer patients (Extended Data Fig 10c).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel i",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel c",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel i",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Moreover, in hematologic cancer patients who recovered from COVID-19, SARS-CoV-2-specific IFN-γ responses correlated with the frequency of HLA-DR+CD38+ CD8 T cells (Fig 4k), but not with HLA-DR+CD38+ CD4 T cells (Extended Data 10d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel k",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel k",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel k",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "This correlation was not seen in patients who died (Extended Data Fig 10e).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "Panel e",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Results are expressed in Spot Forming Units (SFU) per 10^6 PBMCs.Extended Data\nExtended Data Fig. 1 |.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Repeat SARS-CoV-2 RT-PCR testing results (c) from first positive test to last performed test and (d) from first positive test to last positive test. (All) Significance determined by two-sided Mann Whitney test.Extended Data Fig. 2 |.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 3 |.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\n(a) UMAP projections of lymphocytes with indicated protein expression. (b) Frequencies of CD19+, CD3+, CD3+CD8+, and CD3+CD4+ cells of patients in each EMD cluster (Cluster 1 n=7; Cluster 2 n=16; Cluster 3 n=6; Cluster 4 n=10; Cluster 5 n=5). (All) Median and 95% CI shown.Extended Data Fig. 4 |.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 5 |.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 6 |.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\n(a) UMAP projections of lymphocytes with indicated protein expression. (b) Absolute counts of CD19+, CD3+, CD3+CD8+, and CD3+CD4+ cells of patients in each EMD cluster (Cluster 1 n=18; Cluster 2 n=6; Cluster 4 n=26; Cluster 5 n=7). (All) Median and 95% CI shown.Extended Data Fig. 7 |.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 8 |.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 9 |.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 10 |.",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Current or prior smoking (p = 0.028), poor ECOG performance (ECOG 3–4, p=0.001), and active cancer status (p=0.024) (Fig. 1) were all associated with increased COVID-19 mortality.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Similar results were observed in time-to-event analyses using Kaplan Meier methods (Fig. 2a, median overall survival (mOS) not reached for patients with solid cancers vs 47 days for patients with hematologic cancers, p-value=0.030) and Cox regression models (Table 2, HR 2.56, 95% CI 1.19–5.54, p=0.017).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Moreover, patients with hematologic cancers had higher levels of some inflammatory markers on admission laboratory testing, including ferritin, IL-6, and LDH (Fig. 2b, Extended Data Fig. 1a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Both hematologic and solid cancer patients had prolonged viral clearance, with some greater than 60 days (Extended Data Figure 1c,d, Supplemental Table 3).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel c",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Patients with active cancer were older and predominantly female; both groups had a similar timeframe of symptom onset and disease severity (Fig. 3a, Supplemental Table 4).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel a",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "However, cancer patients had a higher all-cause mortality (36.4% versus 11.1%, Fig. 3a), consistent with our COPE cohort and other reported cohorts21, 24,27,28.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel a",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Cancer patients had significantly decreased SARS-CoV-2-specific IgG and IgM antibodies compared to non-cancer patients (Extended Data Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This was largely due to hematologic cancer patients, the majority (6/7) of whom had IgM and IgG levels below the cutoff of positivity of 0.48 arbitrary units (Fig. 3b, Extended Data Fig. 2b), while those with solid cancers had IgG and IgM antibody responses that were more comparable to patients without cancer (Fig. 3b).T cell-depleted phenotype associated with COVID-19 mortality\nPatients who recover from COVID-19 also exhibit SARS-CoV-2-specific CD4 and CD8 T cell responses43,44.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "UMAP (Uniform Manifold Approximation and Projection) representation of 27-parameter flow cytometry data highlighted discrete islands of CD4 and CD8 T cells, and CD19+ B cells (Fig. 3c and Extended Data Fig. 3a).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel a",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Clustering on EMD values identified 5 clusters of patients with similar lymphocyte profiles (Fig. 3c).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Differences between these clusters of patients were driven by both the distribution (Fig. 3d and Extended Data Fig. 3b) and phenotype (Fig. 3e) of CD4, CD8, and B cells.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel d",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "EMD cluster 1 was defined by depleted CD4 and B cells, increased CD8 T cells, and increased activation and effector markers, including PD-1, CX3CR1, Ki67, and HLA-DR (Fig. 3 d,e and Extended Data Fig. 3b).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In contrast, EMD cluster 4 was defined by robust CCR7+CD27+ memory CD4 T cell responses and heterogenous B cell responses; EMD cluster 2 had the most balanced responses, with CD4, CD8, and B cells represented (Fig. 3d,e and Extended Data Fig. 3b).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel d",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "EMD cluster 5 patients with depleted T cells had the highest mortality and disease severity, despite generating SARS-CoV-2-specific IgM and IgG antibodies (Fig. 3f, Extended Data Fig. 5d).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel f",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel d",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "In contrast, EMD clusters 2 and 4, with robust CD4 and/or CD8 T cell responses, had the lowest mortality and a low disease severity (Fig. 3f, Extended Data Fig. 5d).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel f",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel d",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Four out of the 6 solid cancer patients were in EMD cluster 2, with a balanced immune phenotype (Fig. 3e).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Indeed, UMAP projections showed that while solid cancer patients had an immune landscape similar to non-cancer patients, the two hematologic cancer patients demonstrated loss of islands associated with CD4 and B cells (Fig. 3g).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel g",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel g",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel g",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "COVID-19 patients with hematologic cancers had a significantly lower frequency of CD4 and B cells compared to solid cancer patients, non-cancer patients, and healthy donors without COVID-19 (Fig. 3h).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel h",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel h",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel h",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Although limited by sample size, patients with hematologic cancers had low circulating Tfh (PD1+ CXCR5+) and plasmablast responses (CD19+CD27hiCD38hi) and decreased CD138 expression (Extended Data Fig. 4a).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "UMAP clearly separated CX3CR1 and Tbet expressing effector cells from memory CD8 T cells expressing CD27 and TCF-1 (Extended Data Fig. 4b and Fig. 3i).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel b",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel i",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Activated cells, characterized by high HLA-DR, CD38, and Ki67 expression, were identified in clusters 3, 4, and 5 (Extended Data Fig. 4c).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel c",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "CD8 T cell subsets including central memory, effector memory, transitional memory and TEMRA, were similar between patients with and without cancer (Extended Data Fig. 4d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel d",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "However, UMAP representation of non-naïve CD8 data demonstrated preferential enrichment of cells expressing HLA-DR and CD38 in cancer patients compared to non-cancer patients (Fig. 3j).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel j",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel j",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel j",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Indeed, cancer patients had higher frequencies of activated HLA-DR, CD38, and Ki67-expressing FlowSOM clusters (clusters 3, 4, and 5) compared to non-cancer patients and healthy donors (Fig. 3k and Extended Data Fig. 4e).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel k",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel e",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "When stratified by cancer type, the increased HLA-DR and CD38 expression was restricted to the patients with hematologic cancers; patients with solid cancers and those without cancer had comparable levels of activation (Fig. 3l).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel l",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel l",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel l",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The median age of the MSKCC cohort was 65 years, and in contrast to the MESSI cohort at Penn, 81% of the cohort was white (Fig. 4a, Supplemental Table 7,8).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Consistent with the Penn COPE and MESSI cohorts, patients with hematologic cancers did poorly, with a mortality rate of 44.4% (Fig. 4a, Supplemental Table 7).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In the MSKCC cohort, both CD4 and CD8 T cells were significantly decreased in patients with active solid and hematologic cancers, compared with patients in clinical remission (Extended Data Fig. 5a).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel a",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Moreover, despite the fact that a substantial number of patients with hematologic cancers from the MSKCC cohort received convalescent plasma (Supplemental Table 7), they had a significant defect in SARS-CoV-2-specific IgG and IgM responses as compared to solid cancers (Extended Data Fig. 5b).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel b",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "This was independent of disease severity and viral load (Extended Data Fig. 5c,d).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel c",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.EMD and clustering of flow cytometry data from 20 solid cancer, 31 hematologic cancer, and 6 remission patients identified 4 immune phenotypes (Fig. 4b,c and Extended Data Fig. 6a,b) that corresponded to the immune phenotypes 1,2,4, and 5 identified in the Penn-MESSI cohort (Fig. 3c,d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel b",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel a",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Consistent with the Penn data, MSKCC EMD cluster 5, with depleted of CD4 and CD8 T cells and preserved B cells, had the highest mortality of 71%, and was associated with a high disease severity and viral load (Fig 4d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel d",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel d",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel d",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Solid cancer patients in the MSKCC cohort were present in all 4 clusters, with a majority in cluster 4, while hematologic cancer patients were predominantly in clusters 1 and 4 and absent from cluster 2 (Extended Data Figure 7a and b).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel a",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Hematologic cancer patients with phenotype 4 had a mortality of 62% versus 9% in patients with solid cancers (Extended Data Fig. 7c), with a corresponding higher viral load (Extended Data Fig. 7d).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel c",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel d",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Immune phenotype 4 was characterized by robust CD4 responses and decreased, but still present, CD8 responses (Extended Data Fig 6b).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel b",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Within immune phenotype 4, patients with solid and hematologic cancers had similar CD4 and CD8 T cell counts (Extended Data Figure 7e).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel e",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "However, patients with hematologic cancers had near-complete abrogation of B cells (phenotype 4A) that corresponded with a mortality rate of 62% (Extended Fig 7c and f).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel c",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "In contrast, patients with solid cancers had intact B cells counts (phenotype 4B) with a mortality of 9% (Extended Data Fig 7c and f).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel c",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Anti-CD20 therapy (αCD20) with rituximab or obinutuzumab-containing regimens depleted circulating B cells and significantly impaired SARS-CoV-2-specific IgG and IgM responses (Fig. 4e, Extended Data Fig. 8a). αCD20 was not associated with quantitative changes in CD4 and CD8 T cells.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel e",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel a",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "However, patients treated with anti-CD20 therapy exhibited significant reductions in CD4 and CD8 naïve and memory T cells, with a relative skewing towards effector differentiation and an activated HLA-DR+CD38+ phenotype (Extended Data Fig. 8b,c).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel b",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "These changes were not seen in αCD20-treated hematologic patients without COVID-19 (Extended Data Fig. 8d,e).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel d",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Importantly, despite the loss of B cells and humoral immunity, αCD20 therapy was not associated with increased mortality, disease severity, or viral load when compared to chemotherapy or observation (Extended Data Fig. 9a).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel a",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Patients treated with αCD20 therapy were restricted to immune phenotypes 1 and 4, characterized by depleted B cells (Extended Data Fig. 9b).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel b",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "However, phenotype 1, characterized by preserved CD8 T cells, was associated with a lower mortality (Extended Data Fig. 9c).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel c",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Indeed, αCD20 treated patients who survived their COVID-19 hospitalization had higher CD8 T cell counts (Fig 4f), and lower viral load (Extended Data Fig. 9d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel f",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel d",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel f",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel f",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "We extended these analyses to other patients with hematologic cancers, including those on chemotherapy who also had quantitative (Extended Data Fig. 8a), and possibly qualitative B cell defects.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel a",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Hematologic cancer patients who survived had higher CD8 T cell count (Fig. 4g), which was not observed in solid cancer patients (Extended Data Fig. 9e).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel g",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel e",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel g",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel g",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Conversely, CD4 T cell counts were not associated with mortality, and higher B cell counts were associated with increased mortality (Extended Data Fig. 9e, Fig 4g).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel e",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel g",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Classification and Regression Tree Analysis (CART) identified a CD8 T cell level that was predictive of survival after COVID-19 in patients with hematologic cancers (Fig. 4h).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel h",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel h",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel h",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Finally, to assess the antigen-specificity of T cell responses in SARS-CoV-2 infected cancer patients, we stimulated PBMC from 13 hematologic cancer patients and 10 solid cancer patients using MHC-I and MHC-II restricted SARS-CoV-2 and EBV peptide pools and measured IFN-γ and IL-2 responses using ELISpot (Extended Data Figure 10a).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "Panel a",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "After background (no-peptide) subtraction, 10 out of 13 (77%) of hematologic cancer patients had SARS-CoV-2- specific IL-2 and/or IFN-γ responses (Figure 4i), including 8 out of 8 (100%) of patients treated with αCD20 (Figure 4j, Extended Data Fig 10b).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel i",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel j",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel b",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel i",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In general, these SARS-CoV-2-specific responses were greater in magnitude than EBV-specific responses (Figure 4i), and hematologic cancer patients had greater SARS-CoV-2 antigen-specific T cell responses than solid cancer patients (Extended Data Fig 10c).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel i",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel c",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel i",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Moreover, in hematologic cancer patients who recovered from COVID-19, SARS-CoV-2-specific IFN-γ responses correlated with the frequency of HLA-DR+CD38+ CD8 T cells (Fig 4k), but not with HLA-DR+CD38+ CD4 T cells (Extended Data 10d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel k",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel k",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel k",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "This correlation was not seen in patients who died (Extended Data Fig 10e).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "Panel e",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Results are expressed in Spot Forming Units (SFU) per 10^6 PBMCs.Extended Data\nExtended Data Fig. 1 |.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Repeat SARS-CoV-2 RT-PCR testing results (c) from first positive test to last performed test and (d) from first positive test to last positive test. (All) Significance determined by two-sided Mann Whitney test.Extended Data Fig. 2 |.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 3 |.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\n(a) UMAP projections of lymphocytes with indicated protein expression. (b) Frequencies of CD19+, CD3+, CD3+CD8+, and CD3+CD4+ cells of patients in each EMD cluster (Cluster 1 n=7; Cluster 2 n=16; Cluster 3 n=6; Cluster 4 n=10; Cluster 5 n=5). (All) Median and 95% CI shown.Extended Data Fig. 4 |.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 5 |.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 6 |.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\n(a) UMAP projections of lymphocytes with indicated protein expression. (b) Absolute counts of CD19+, CD3+, CD3+CD8+, and CD3+CD4+ cells of patients in each EMD cluster (Cluster 1 n=18; Cluster 2 n=6; Cluster 4 n=26; Cluster 5 n=7). (All) Median and 95% CI shown.Extended Data Fig. 7 |.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 8 |.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 9 |.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 10 |.",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Current or prior smoking (p = 0.028), poor ECOG performance (ECOG 3–4, p=0.001), and active cancer status (p=0.024) (Fig. 1) were all associated with increased COVID-19 mortality.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Similar results were observed in time-to-event analyses using Kaplan Meier methods (Fig. 2a, median overall survival (mOS) not reached for patients with solid cancers vs 47 days for patients with hematologic cancers, p-value=0.030) and Cox regression models (Table 2, HR 2.56, 95% CI 1.19–5.54, p=0.017).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Moreover, patients with hematologic cancers had higher levels of some inflammatory markers on admission laboratory testing, including ferritin, IL-6, and LDH (Fig. 2b, Extended Data Fig. 1a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Both hematologic and solid cancer patients had prolonged viral clearance, with some greater than 60 days (Extended Data Figure 1c,d, Supplemental Table 3).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel c",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Patients with active cancer were older and predominantly female; both groups had a similar timeframe of symptom onset and disease severity (Fig. 3a, Supplemental Table 4).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel a",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "However, cancer patients had a higher all-cause mortality (36.4% versus 11.1%, Fig. 3a), consistent with our COPE cohort and other reported cohorts21, 24,27,28.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel a",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Cancer patients had significantly decreased SARS-CoV-2-specific IgG and IgM antibodies compared to non-cancer patients (Extended Data Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This was largely due to hematologic cancer patients, the majority (6/7) of whom had IgM and IgG levels below the cutoff of positivity of 0.48 arbitrary units (Fig. 3b, Extended Data Fig. 2b), while those with solid cancers had IgG and IgM antibody responses that were more comparable to patients without cancer (Fig. 3b).T cell-depleted phenotype associated with COVID-19 mortality\nPatients who recover from COVID-19 also exhibit SARS-CoV-2-specific CD4 and CD8 T cell responses43,44.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "UMAP (Uniform Manifold Approximation and Projection) representation of 27-parameter flow cytometry data highlighted discrete islands of CD4 and CD8 T cells, and CD19+ B cells (Fig. 3c and Extended Data Fig. 3a).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel a",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Clustering on EMD values identified 5 clusters of patients with similar lymphocyte profiles (Fig. 3c).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Differences between these clusters of patients were driven by both the distribution (Fig. 3d and Extended Data Fig. 3b) and phenotype (Fig. 3e) of CD4, CD8, and B cells.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel d",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "EMD cluster 1 was defined by depleted CD4 and B cells, increased CD8 T cells, and increased activation and effector markers, including PD-1, CX3CR1, Ki67, and HLA-DR (Fig. 3 d,e and Extended Data Fig. 3b).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In contrast, EMD cluster 4 was defined by robust CCR7+CD27+ memory CD4 T cell responses and heterogenous B cell responses; EMD cluster 2 had the most balanced responses, with CD4, CD8, and B cells represented (Fig. 3d,e and Extended Data Fig. 3b).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel d",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "EMD cluster 5 patients with depleted T cells had the highest mortality and disease severity, despite generating SARS-CoV-2-specific IgM and IgG antibodies (Fig. 3f, Extended Data Fig. 5d).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel f",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel d",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "In contrast, EMD clusters 2 and 4, with robust CD4 and/or CD8 T cell responses, had the lowest mortality and a low disease severity (Fig. 3f, Extended Data Fig. 5d).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel f",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel d",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Four out of the 6 solid cancer patients were in EMD cluster 2, with a balanced immune phenotype (Fig. 3e).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Indeed, UMAP projections showed that while solid cancer patients had an immune landscape similar to non-cancer patients, the two hematologic cancer patients demonstrated loss of islands associated with CD4 and B cells (Fig. 3g).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel g",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel g",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel g",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "COVID-19 patients with hematologic cancers had a significantly lower frequency of CD4 and B cells compared to solid cancer patients, non-cancer patients, and healthy donors without COVID-19 (Fig. 3h).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel h",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel h",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel h",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Although limited by sample size, patients with hematologic cancers had low circulating Tfh (PD1+ CXCR5+) and plasmablast responses (CD19+CD27hiCD38hi) and decreased CD138 expression (Extended Data Fig. 4a).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "UMAP clearly separated CX3CR1 and Tbet expressing effector cells from memory CD8 T cells expressing CD27 and TCF-1 (Extended Data Fig. 4b and Fig. 3i).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel b",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel i",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Activated cells, characterized by high HLA-DR, CD38, and Ki67 expression, were identified in clusters 3, 4, and 5 (Extended Data Fig. 4c).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel c",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "CD8 T cell subsets including central memory, effector memory, transitional memory and TEMRA, were similar between patients with and without cancer (Extended Data Fig. 4d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel d",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "However, UMAP representation of non-naïve CD8 data demonstrated preferential enrichment of cells expressing HLA-DR and CD38 in cancer patients compared to non-cancer patients (Fig. 3j).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel j",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel j",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel j",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Indeed, cancer patients had higher frequencies of activated HLA-DR, CD38, and Ki67-expressing FlowSOM clusters (clusters 3, 4, and 5) compared to non-cancer patients and healthy donors (Fig. 3k and Extended Data Fig. 4e).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel k",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel e",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "When stratified by cancer type, the increased HLA-DR and CD38 expression was restricted to the patients with hematologic cancers; patients with solid cancers and those without cancer had comparable levels of activation (Fig. 3l).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel l",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel l",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel l",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The median age of the MSKCC cohort was 65 years, and in contrast to the MESSI cohort at Penn, 81% of the cohort was white (Fig. 4a, Supplemental Table 7,8).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Consistent with the Penn COPE and MESSI cohorts, patients with hematologic cancers did poorly, with a mortality rate of 44.4% (Fig. 4a, Supplemental Table 7).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In the MSKCC cohort, both CD4 and CD8 T cells were significantly decreased in patients with active solid and hematologic cancers, compared with patients in clinical remission (Extended Data Fig. 5a).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel a",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Moreover, despite the fact that a substantial number of patients with hematologic cancers from the MSKCC cohort received convalescent plasma (Supplemental Table 7), they had a significant defect in SARS-CoV-2-specific IgG and IgM responses as compared to solid cancers (Extended Data Fig. 5b).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel b",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "This was independent of disease severity and viral load (Extended Data Fig. 5c,d).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel c",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.EMD and clustering of flow cytometry data from 20 solid cancer, 31 hematologic cancer, and 6 remission patients identified 4 immune phenotypes (Fig. 4b,c and Extended Data Fig. 6a,b) that corresponded to the immune phenotypes 1,2,4, and 5 identified in the Penn-MESSI cohort (Fig. 3c,d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel b",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel a",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Consistent with the Penn data, MSKCC EMD cluster 5, with depleted of CD4 and CD8 T cells and preserved B cells, had the highest mortality of 71%, and was associated with a high disease severity and viral load (Fig 4d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel d",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel d",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel d",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Solid cancer patients in the MSKCC cohort were present in all 4 clusters, with a majority in cluster 4, while hematologic cancer patients were predominantly in clusters 1 and 4 and absent from cluster 2 (Extended Data Figure 7a and b).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel a",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Hematologic cancer patients with phenotype 4 had a mortality of 62% versus 9% in patients with solid cancers (Extended Data Fig. 7c), with a corresponding higher viral load (Extended Data Fig. 7d).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel c",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel d",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Immune phenotype 4 was characterized by robust CD4 responses and decreased, but still present, CD8 responses (Extended Data Fig 6b).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel b",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Within immune phenotype 4, patients with solid and hematologic cancers had similar CD4 and CD8 T cell counts (Extended Data Figure 7e).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel e",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "However, patients with hematologic cancers had near-complete abrogation of B cells (phenotype 4A) that corresponded with a mortality rate of 62% (Extended Fig 7c and f).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel c",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "In contrast, patients with solid cancers had intact B cells counts (phenotype 4B) with a mortality of 9% (Extended Data Fig 7c and f).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel c",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Anti-CD20 therapy (αCD20) with rituximab or obinutuzumab-containing regimens depleted circulating B cells and significantly impaired SARS-CoV-2-specific IgG and IgM responses (Fig. 4e, Extended Data Fig. 8a). αCD20 was not associated with quantitative changes in CD4 and CD8 T cells.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel e",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel a",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "However, patients treated with anti-CD20 therapy exhibited significant reductions in CD4 and CD8 naïve and memory T cells, with a relative skewing towards effector differentiation and an activated HLA-DR+CD38+ phenotype (Extended Data Fig. 8b,c).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel b",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "These changes were not seen in αCD20-treated hematologic patients without COVID-19 (Extended Data Fig. 8d,e).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel d",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Importantly, despite the loss of B cells and humoral immunity, αCD20 therapy was not associated with increased mortality, disease severity, or viral load when compared to chemotherapy or observation (Extended Data Fig. 9a).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel a",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Patients treated with αCD20 therapy were restricted to immune phenotypes 1 and 4, characterized by depleted B cells (Extended Data Fig. 9b).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel b",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "However, phenotype 1, characterized by preserved CD8 T cells, was associated with a lower mortality (Extended Data Fig. 9c).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel c",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Indeed, αCD20 treated patients who survived their COVID-19 hospitalization had higher CD8 T cell counts (Fig 4f), and lower viral load (Extended Data Fig. 9d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel f",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel d",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel f",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel f",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "We extended these analyses to other patients with hematologic cancers, including those on chemotherapy who also had quantitative (Extended Data Fig. 8a), and possibly qualitative B cell defects.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel a",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Hematologic cancer patients who survived had higher CD8 T cell count (Fig. 4g), which was not observed in solid cancer patients (Extended Data Fig. 9e).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel g",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel e",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel g",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel g",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Conversely, CD4 T cell counts were not associated with mortality, and higher B cell counts were associated with increased mortality (Extended Data Fig. 9e, Fig 4g).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel e",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel g",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Classification and Regression Tree Analysis (CART) identified a CD8 T cell level that was predictive of survival after COVID-19 in patients with hematologic cancers (Fig. 4h).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel h",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel h",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel h",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Finally, to assess the antigen-specificity of T cell responses in SARS-CoV-2 infected cancer patients, we stimulated PBMC from 13 hematologic cancer patients and 10 solid cancer patients using MHC-I and MHC-II restricted SARS-CoV-2 and EBV peptide pools and measured IFN-γ and IL-2 responses using ELISpot (Extended Data Figure 10a).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "Panel a",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "After background (no-peptide) subtraction, 10 out of 13 (77%) of hematologic cancer patients had SARS-CoV-2- specific IL-2 and/or IFN-γ responses (Figure 4i), including 8 out of 8 (100%) of patients treated with αCD20 (Figure 4j, Extended Data Fig 10b).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel i",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel j",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel b",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel i",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In general, these SARS-CoV-2-specific responses were greater in magnitude than EBV-specific responses (Figure 4i), and hematologic cancer patients had greater SARS-CoV-2 antigen-specific T cell responses than solid cancer patients (Extended Data Fig 10c).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel i",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel c",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel i",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Moreover, in hematologic cancer patients who recovered from COVID-19, SARS-CoV-2-specific IFN-γ responses correlated with the frequency of HLA-DR+CD38+ CD8 T cells (Fig 4k), but not with HLA-DR+CD38+ CD4 T cells (Extended Data 10d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel k",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel k",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel k",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "This correlation was not seen in patients who died (Extended Data Fig 10e).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "Panel e",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Results are expressed in Spot Forming Units (SFU) per 10^6 PBMCs.Extended Data\nExtended Data Fig. 1 |.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Repeat SARS-CoV-2 RT-PCR testing results (c) from first positive test to last performed test and (d) from first positive test to last positive test. (All) Significance determined by two-sided Mann Whitney test.Extended Data Fig. 2 |.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 3 |.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\n(a) UMAP projections of lymphocytes with indicated protein expression. (b) Frequencies of CD19+, CD3+, CD3+CD8+, and CD3+CD4+ cells of patients in each EMD cluster (Cluster 1 n=7; Cluster 2 n=16; Cluster 3 n=6; Cluster 4 n=10; Cluster 5 n=5). (All) Median and 95% CI shown.Extended Data Fig. 4 |.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 5 |.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 6 |.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\n(a) UMAP projections of lymphocytes with indicated protein expression. (b) Absolute counts of CD19+, CD3+, CD3+CD8+, and CD3+CD4+ cells of patients in each EMD cluster (Cluster 1 n=18; Cluster 2 n=6; Cluster 4 n=26; Cluster 5 n=7). (All) Median and 95% CI shown.Extended Data Fig. 7 |.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 8 |.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 9 |.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 10 |.",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Current or prior smoking (p = 0.028), poor ECOG performance (ECOG 3–4, p=0.001), and active cancer status (p=0.024) (Fig. 1) were all associated with increased COVID-19 mortality.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Similar results were observed in time-to-event analyses using Kaplan Meier methods (Fig. 2a, median overall survival (mOS) not reached for patients with solid cancers vs 47 days for patients with hematologic cancers, p-value=0.030) and Cox regression models (Table 2, HR 2.56, 95% CI 1.19–5.54, p=0.017).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Moreover, patients with hematologic cancers had higher levels of some inflammatory markers on admission laboratory testing, including ferritin, IL-6, and LDH (Fig. 2b, Extended Data Fig. 1a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Both hematologic and solid cancer patients had prolonged viral clearance, with some greater than 60 days (Extended Data Figure 1c,d, Supplemental Table 3).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel c",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Patients with active cancer were older and predominantly female; both groups had a similar timeframe of symptom onset and disease severity (Fig. 3a, Supplemental Table 4).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel a",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "However, cancer patients had a higher all-cause mortality (36.4% versus 11.1%, Fig. 3a), consistent with our COPE cohort and other reported cohorts21, 24,27,28.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel a",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Cancer patients had significantly decreased SARS-CoV-2-specific IgG and IgM antibodies compared to non-cancer patients (Extended Data Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This was largely due to hematologic cancer patients, the majority (6/7) of whom had IgM and IgG levels below the cutoff of positivity of 0.48 arbitrary units (Fig. 3b, Extended Data Fig. 2b), while those with solid cancers had IgG and IgM antibody responses that were more comparable to patients without cancer (Fig. 3b).T cell-depleted phenotype associated with COVID-19 mortality\nPatients who recover from COVID-19 also exhibit SARS-CoV-2-specific CD4 and CD8 T cell responses43,44.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "UMAP (Uniform Manifold Approximation and Projection) representation of 27-parameter flow cytometry data highlighted discrete islands of CD4 and CD8 T cells, and CD19+ B cells (Fig. 3c and Extended Data Fig. 3a).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel a",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Clustering on EMD values identified 5 clusters of patients with similar lymphocyte profiles (Fig. 3c).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Differences between these clusters of patients were driven by both the distribution (Fig. 3d and Extended Data Fig. 3b) and phenotype (Fig. 3e) of CD4, CD8, and B cells.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel d",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "EMD cluster 1 was defined by depleted CD4 and B cells, increased CD8 T cells, and increased activation and effector markers, including PD-1, CX3CR1, Ki67, and HLA-DR (Fig. 3 d,e and Extended Data Fig. 3b).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In contrast, EMD cluster 4 was defined by robust CCR7+CD27+ memory CD4 T cell responses and heterogenous B cell responses; EMD cluster 2 had the most balanced responses, with CD4, CD8, and B cells represented (Fig. 3d,e and Extended Data Fig. 3b).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel d",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "EMD cluster 5 patients with depleted T cells had the highest mortality and disease severity, despite generating SARS-CoV-2-specific IgM and IgG antibodies (Fig. 3f, Extended Data Fig. 5d).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel f",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel d",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "In contrast, EMD clusters 2 and 4, with robust CD4 and/or CD8 T cell responses, had the lowest mortality and a low disease severity (Fig. 3f, Extended Data Fig. 5d).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel f",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel d",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Four out of the 6 solid cancer patients were in EMD cluster 2, with a balanced immune phenotype (Fig. 3e).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Indeed, UMAP projections showed that while solid cancer patients had an immune landscape similar to non-cancer patients, the two hematologic cancer patients demonstrated loss of islands associated with CD4 and B cells (Fig. 3g).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel g",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel g",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel g",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "COVID-19 patients with hematologic cancers had a significantly lower frequency of CD4 and B cells compared to solid cancer patients, non-cancer patients, and healthy donors without COVID-19 (Fig. 3h).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel h",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel h",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel h",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Although limited by sample size, patients with hematologic cancers had low circulating Tfh (PD1+ CXCR5+) and plasmablast responses (CD19+CD27hiCD38hi) and decreased CD138 expression (Extended Data Fig. 4a).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "UMAP clearly separated CX3CR1 and Tbet expressing effector cells from memory CD8 T cells expressing CD27 and TCF-1 (Extended Data Fig. 4b and Fig. 3i).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel b",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel i",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Activated cells, characterized by high HLA-DR, CD38, and Ki67 expression, were identified in clusters 3, 4, and 5 (Extended Data Fig. 4c).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel c",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "CD8 T cell subsets including central memory, effector memory, transitional memory and TEMRA, were similar between patients with and without cancer (Extended Data Fig. 4d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel d",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "However, UMAP representation of non-naïve CD8 data demonstrated preferential enrichment of cells expressing HLA-DR and CD38 in cancer patients compared to non-cancer patients (Fig. 3j).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel j",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel j",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel j",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Indeed, cancer patients had higher frequencies of activated HLA-DR, CD38, and Ki67-expressing FlowSOM clusters (clusters 3, 4, and 5) compared to non-cancer patients and healthy donors (Fig. 3k and Extended Data Fig. 4e).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel k",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel e",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "When stratified by cancer type, the increased HLA-DR and CD38 expression was restricted to the patients with hematologic cancers; patients with solid cancers and those without cancer had comparable levels of activation (Fig. 3l).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel l",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel l",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel l",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The median age of the MSKCC cohort was 65 years, and in contrast to the MESSI cohort at Penn, 81% of the cohort was white (Fig. 4a, Supplemental Table 7,8).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Consistent with the Penn COPE and MESSI cohorts, patients with hematologic cancers did poorly, with a mortality rate of 44.4% (Fig. 4a, Supplemental Table 7).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In the MSKCC cohort, both CD4 and CD8 T cells were significantly decreased in patients with active solid and hematologic cancers, compared with patients in clinical remission (Extended Data Fig. 5a).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel a",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Moreover, despite the fact that a substantial number of patients with hematologic cancers from the MSKCC cohort received convalescent plasma (Supplemental Table 7), they had a significant defect in SARS-CoV-2-specific IgG and IgM responses as compared to solid cancers (Extended Data Fig. 5b).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel b",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "This was independent of disease severity and viral load (Extended Data Fig. 5c,d).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel c",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.EMD and clustering of flow cytometry data from 20 solid cancer, 31 hematologic cancer, and 6 remission patients identified 4 immune phenotypes (Fig. 4b,c and Extended Data Fig. 6a,b) that corresponded to the immune phenotypes 1,2,4, and 5 identified in the Penn-MESSI cohort (Fig. 3c,d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel b",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel a",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Consistent with the Penn data, MSKCC EMD cluster 5, with depleted of CD4 and CD8 T cells and preserved B cells, had the highest mortality of 71%, and was associated with a high disease severity and viral load (Fig 4d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel d",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel d",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel d",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Solid cancer patients in the MSKCC cohort were present in all 4 clusters, with a majority in cluster 4, while hematologic cancer patients were predominantly in clusters 1 and 4 and absent from cluster 2 (Extended Data Figure 7a and b).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel a",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Hematologic cancer patients with phenotype 4 had a mortality of 62% versus 9% in patients with solid cancers (Extended Data Fig. 7c), with a corresponding higher viral load (Extended Data Fig. 7d).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel c",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel d",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Immune phenotype 4 was characterized by robust CD4 responses and decreased, but still present, CD8 responses (Extended Data Fig 6b).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel b",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Within immune phenotype 4, patients with solid and hematologic cancers had similar CD4 and CD8 T cell counts (Extended Data Figure 7e).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel e",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "However, patients with hematologic cancers had near-complete abrogation of B cells (phenotype 4A) that corresponded with a mortality rate of 62% (Extended Fig 7c and f).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel c",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "In contrast, patients with solid cancers had intact B cells counts (phenotype 4B) with a mortality of 9% (Extended Data Fig 7c and f).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel c",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Anti-CD20 therapy (αCD20) with rituximab or obinutuzumab-containing regimens depleted circulating B cells and significantly impaired SARS-CoV-2-specific IgG and IgM responses (Fig. 4e, Extended Data Fig. 8a). αCD20 was not associated with quantitative changes in CD4 and CD8 T cells.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel e",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel a",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "However, patients treated with anti-CD20 therapy exhibited significant reductions in CD4 and CD8 naïve and memory T cells, with a relative skewing towards effector differentiation and an activated HLA-DR+CD38+ phenotype (Extended Data Fig. 8b,c).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel b",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "These changes were not seen in αCD20-treated hematologic patients without COVID-19 (Extended Data Fig. 8d,e).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel d",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Importantly, despite the loss of B cells and humoral immunity, αCD20 therapy was not associated with increased mortality, disease severity, or viral load when compared to chemotherapy or observation (Extended Data Fig. 9a).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel a",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Patients treated with αCD20 therapy were restricted to immune phenotypes 1 and 4, characterized by depleted B cells (Extended Data Fig. 9b).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel b",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "However, phenotype 1, characterized by preserved CD8 T cells, was associated with a lower mortality (Extended Data Fig. 9c).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel c",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Indeed, αCD20 treated patients who survived their COVID-19 hospitalization had higher CD8 T cell counts (Fig 4f), and lower viral load (Extended Data Fig. 9d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel f",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel d",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel f",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel f",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "We extended these analyses to other patients with hematologic cancers, including those on chemotherapy who also had quantitative (Extended Data Fig. 8a), and possibly qualitative B cell defects.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel a",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Hematologic cancer patients who survived had higher CD8 T cell count (Fig. 4g), which was not observed in solid cancer patients (Extended Data Fig. 9e).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel g",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel e",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel g",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel g",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Conversely, CD4 T cell counts were not associated with mortality, and higher B cell counts were associated with increased mortality (Extended Data Fig. 9e, Fig 4g).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel e",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel g",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Classification and Regression Tree Analysis (CART) identified a CD8 T cell level that was predictive of survival after COVID-19 in patients with hematologic cancers (Fig. 4h).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel h",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel h",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel h",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Finally, to assess the antigen-specificity of T cell responses in SARS-CoV-2 infected cancer patients, we stimulated PBMC from 13 hematologic cancer patients and 10 solid cancer patients using MHC-I and MHC-II restricted SARS-CoV-2 and EBV peptide pools and measured IFN-γ and IL-2 responses using ELISpot (Extended Data Figure 10a).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "Panel a",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "After background (no-peptide) subtraction, 10 out of 13 (77%) of hematologic cancer patients had SARS-CoV-2- specific IL-2 and/or IFN-γ responses (Figure 4i), including 8 out of 8 (100%) of patients treated with αCD20 (Figure 4j, Extended Data Fig 10b).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel i",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel j",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel b",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel i",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In general, these SARS-CoV-2-specific responses were greater in magnitude than EBV-specific responses (Figure 4i), and hematologic cancer patients had greater SARS-CoV-2 antigen-specific T cell responses than solid cancer patients (Extended Data Fig 10c).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel i",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel c",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel i",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Moreover, in hematologic cancer patients who recovered from COVID-19, SARS-CoV-2-specific IFN-γ responses correlated with the frequency of HLA-DR+CD38+ CD8 T cells (Fig 4k), but not with HLA-DR+CD38+ CD4 T cells (Extended Data 10d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel k",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel k",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel k",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "This correlation was not seen in patients who died (Extended Data Fig 10e).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "Panel e",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Results are expressed in Spot Forming Units (SFU) per 10^6 PBMCs.Extended Data\nExtended Data Fig. 1 |.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Repeat SARS-CoV-2 RT-PCR testing results (c) from first positive test to last performed test and (d) from first positive test to last positive test. (All) Significance determined by two-sided Mann Whitney test.Extended Data Fig. 2 |.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 3 |.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\n(a) UMAP projections of lymphocytes with indicated protein expression. (b) Frequencies of CD19+, CD3+, CD3+CD8+, and CD3+CD4+ cells of patients in each EMD cluster (Cluster 1 n=7; Cluster 2 n=16; Cluster 3 n=6; Cluster 4 n=10; Cluster 5 n=5). (All) Median and 95% CI shown.Extended Data Fig. 4 |.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 5 |.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 6 |.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\n(a) UMAP projections of lymphocytes with indicated protein expression. (b) Absolute counts of CD19+, CD3+, CD3+CD8+, and CD3+CD4+ cells of patients in each EMD cluster (Cluster 1 n=18; Cluster 2 n=6; Cluster 4 n=26; Cluster 5 n=7). (All) Median and 95% CI shown.Extended Data Fig. 7 |.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 8 |.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 9 |.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 10 |.",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Current or prior smoking (p = 0.028), poor ECOG performance (ECOG 3–4, p=0.001), and active cancer status (p=0.024) (Fig. 1) were all associated with increased COVID-19 mortality.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Similar results were observed in time-to-event analyses using Kaplan Meier methods (Fig. 2a, median overall survival (mOS) not reached for patients with solid cancers vs 47 days for patients with hematologic cancers, p-value=0.030) and Cox regression models (Table 2, HR 2.56, 95% CI 1.19–5.54, p=0.017).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Moreover, patients with hematologic cancers had higher levels of some inflammatory markers on admission laboratory testing, including ferritin, IL-6, and LDH (Fig. 2b, Extended Data Fig. 1a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Both hematologic and solid cancer patients had prolonged viral clearance, with some greater than 60 days (Extended Data Figure 1c,d, Supplemental Table 3).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel c",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Patients with active cancer were older and predominantly female; both groups had a similar timeframe of symptom onset and disease severity (Fig. 3a, Supplemental Table 4).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel a",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "However, cancer patients had a higher all-cause mortality (36.4% versus 11.1%, Fig. 3a), consistent with our COPE cohort and other reported cohorts21, 24,27,28.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel a",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Cancer patients had significantly decreased SARS-CoV-2-specific IgG and IgM antibodies compared to non-cancer patients (Extended Data Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This was largely due to hematologic cancer patients, the majority (6/7) of whom had IgM and IgG levels below the cutoff of positivity of 0.48 arbitrary units (Fig. 3b, Extended Data Fig. 2b), while those with solid cancers had IgG and IgM antibody responses that were more comparable to patients without cancer (Fig. 3b).T cell-depleted phenotype associated with COVID-19 mortality\nPatients who recover from COVID-19 also exhibit SARS-CoV-2-specific CD4 and CD8 T cell responses43,44.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "UMAP (Uniform Manifold Approximation and Projection) representation of 27-parameter flow cytometry data highlighted discrete islands of CD4 and CD8 T cells, and CD19+ B cells (Fig. 3c and Extended Data Fig. 3a).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel a",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Clustering on EMD values identified 5 clusters of patients with similar lymphocyte profiles (Fig. 3c).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Differences between these clusters of patients were driven by both the distribution (Fig. 3d and Extended Data Fig. 3b) and phenotype (Fig. 3e) of CD4, CD8, and B cells.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel d",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "EMD cluster 1 was defined by depleted CD4 and B cells, increased CD8 T cells, and increased activation and effector markers, including PD-1, CX3CR1, Ki67, and HLA-DR (Fig. 3 d,e and Extended Data Fig. 3b).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In contrast, EMD cluster 4 was defined by robust CCR7+CD27+ memory CD4 T cell responses and heterogenous B cell responses; EMD cluster 2 had the most balanced responses, with CD4, CD8, and B cells represented (Fig. 3d,e and Extended Data Fig. 3b).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel d",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "EMD cluster 5 patients with depleted T cells had the highest mortality and disease severity, despite generating SARS-CoV-2-specific IgM and IgG antibodies (Fig. 3f, Extended Data Fig. 5d).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel f",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel d",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "In contrast, EMD clusters 2 and 4, with robust CD4 and/or CD8 T cell responses, had the lowest mortality and a low disease severity (Fig. 3f, Extended Data Fig. 5d).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel f",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel d",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Four out of the 6 solid cancer patients were in EMD cluster 2, with a balanced immune phenotype (Fig. 3e).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Indeed, UMAP projections showed that while solid cancer patients had an immune landscape similar to non-cancer patients, the two hematologic cancer patients demonstrated loss of islands associated with CD4 and B cells (Fig. 3g).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel g",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel g",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel g",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "COVID-19 patients with hematologic cancers had a significantly lower frequency of CD4 and B cells compared to solid cancer patients, non-cancer patients, and healthy donors without COVID-19 (Fig. 3h).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel h",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel h",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel h",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Although limited by sample size, patients with hematologic cancers had low circulating Tfh (PD1+ CXCR5+) and plasmablast responses (CD19+CD27hiCD38hi) and decreased CD138 expression (Extended Data Fig. 4a).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "UMAP clearly separated CX3CR1 and Tbet expressing effector cells from memory CD8 T cells expressing CD27 and TCF-1 (Extended Data Fig. 4b and Fig. 3i).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel b",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel i",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Activated cells, characterized by high HLA-DR, CD38, and Ki67 expression, were identified in clusters 3, 4, and 5 (Extended Data Fig. 4c).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel c",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "CD8 T cell subsets including central memory, effector memory, transitional memory and TEMRA, were similar between patients with and without cancer (Extended Data Fig. 4d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel d",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "However, UMAP representation of non-naïve CD8 data demonstrated preferential enrichment of cells expressing HLA-DR and CD38 in cancer patients compared to non-cancer patients (Fig. 3j).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel j",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel j",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel j",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Indeed, cancer patients had higher frequencies of activated HLA-DR, CD38, and Ki67-expressing FlowSOM clusters (clusters 3, 4, and 5) compared to non-cancer patients and healthy donors (Fig. 3k and Extended Data Fig. 4e).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel k",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel e",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "When stratified by cancer type, the increased HLA-DR and CD38 expression was restricted to the patients with hematologic cancers; patients with solid cancers and those without cancer had comparable levels of activation (Fig. 3l).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel l",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel l",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel l",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The median age of the MSKCC cohort was 65 years, and in contrast to the MESSI cohort at Penn, 81% of the cohort was white (Fig. 4a, Supplemental Table 7,8).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Consistent with the Penn COPE and MESSI cohorts, patients with hematologic cancers did poorly, with a mortality rate of 44.4% (Fig. 4a, Supplemental Table 7).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In the MSKCC cohort, both CD4 and CD8 T cells were significantly decreased in patients with active solid and hematologic cancers, compared with patients in clinical remission (Extended Data Fig. 5a).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel a",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Moreover, despite the fact that a substantial number of patients with hematologic cancers from the MSKCC cohort received convalescent plasma (Supplemental Table 7), they had a significant defect in SARS-CoV-2-specific IgG and IgM responses as compared to solid cancers (Extended Data Fig. 5b).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel b",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "This was independent of disease severity and viral load (Extended Data Fig. 5c,d).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel c",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.EMD and clustering of flow cytometry data from 20 solid cancer, 31 hematologic cancer, and 6 remission patients identified 4 immune phenotypes (Fig. 4b,c and Extended Data Fig. 6a,b) that corresponded to the immune phenotypes 1,2,4, and 5 identified in the Penn-MESSI cohort (Fig. 3c,d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel b",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel a",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Consistent with the Penn data, MSKCC EMD cluster 5, with depleted of CD4 and CD8 T cells and preserved B cells, had the highest mortality of 71%, and was associated with a high disease severity and viral load (Fig 4d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel d",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel d",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel d",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Solid cancer patients in the MSKCC cohort were present in all 4 clusters, with a majority in cluster 4, while hematologic cancer patients were predominantly in clusters 1 and 4 and absent from cluster 2 (Extended Data Figure 7a and b).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel a",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Hematologic cancer patients with phenotype 4 had a mortality of 62% versus 9% in patients with solid cancers (Extended Data Fig. 7c), with a corresponding higher viral load (Extended Data Fig. 7d).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel c",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel d",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Immune phenotype 4 was characterized by robust CD4 responses and decreased, but still present, CD8 responses (Extended Data Fig 6b).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel b",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Within immune phenotype 4, patients with solid and hematologic cancers had similar CD4 and CD8 T cell counts (Extended Data Figure 7e).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel e",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "However, patients with hematologic cancers had near-complete abrogation of B cells (phenotype 4A) that corresponded with a mortality rate of 62% (Extended Fig 7c and f).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel c",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "In contrast, patients with solid cancers had intact B cells counts (phenotype 4B) with a mortality of 9% (Extended Data Fig 7c and f).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel c",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Anti-CD20 therapy (αCD20) with rituximab or obinutuzumab-containing regimens depleted circulating B cells and significantly impaired SARS-CoV-2-specific IgG and IgM responses (Fig. 4e, Extended Data Fig. 8a). αCD20 was not associated with quantitative changes in CD4 and CD8 T cells.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel e",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel a",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "However, patients treated with anti-CD20 therapy exhibited significant reductions in CD4 and CD8 naïve and memory T cells, with a relative skewing towards effector differentiation and an activated HLA-DR+CD38+ phenotype (Extended Data Fig. 8b,c).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel b",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "These changes were not seen in αCD20-treated hematologic patients without COVID-19 (Extended Data Fig. 8d,e).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel d",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Importantly, despite the loss of B cells and humoral immunity, αCD20 therapy was not associated with increased mortality, disease severity, or viral load when compared to chemotherapy or observation (Extended Data Fig. 9a).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel a",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Patients treated with αCD20 therapy were restricted to immune phenotypes 1 and 4, characterized by depleted B cells (Extended Data Fig. 9b).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel b",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "However, phenotype 1, characterized by preserved CD8 T cells, was associated with a lower mortality (Extended Data Fig. 9c).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel c",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Indeed, αCD20 treated patients who survived their COVID-19 hospitalization had higher CD8 T cell counts (Fig 4f), and lower viral load (Extended Data Fig. 9d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel f",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel d",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel f",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel f",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "We extended these analyses to other patients with hematologic cancers, including those on chemotherapy who also had quantitative (Extended Data Fig. 8a), and possibly qualitative B cell defects.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel a",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Hematologic cancer patients who survived had higher CD8 T cell count (Fig. 4g), which was not observed in solid cancer patients (Extended Data Fig. 9e).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel g",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel e",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel g",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel g",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Conversely, CD4 T cell counts were not associated with mortality, and higher B cell counts were associated with increased mortality (Extended Data Fig. 9e, Fig 4g).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel e",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel g",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Classification and Regression Tree Analysis (CART) identified a CD8 T cell level that was predictive of survival after COVID-19 in patients with hematologic cancers (Fig. 4h).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel h",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel h",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel h",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Finally, to assess the antigen-specificity of T cell responses in SARS-CoV-2 infected cancer patients, we stimulated PBMC from 13 hematologic cancer patients and 10 solid cancer patients using MHC-I and MHC-II restricted SARS-CoV-2 and EBV peptide pools and measured IFN-γ and IL-2 responses using ELISpot (Extended Data Figure 10a).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "Panel a",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "After background (no-peptide) subtraction, 10 out of 13 (77%) of hematologic cancer patients had SARS-CoV-2- specific IL-2 and/or IFN-γ responses (Figure 4i), including 8 out of 8 (100%) of patients treated with αCD20 (Figure 4j, Extended Data Fig 10b).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel i",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel j",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel b",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel i",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In general, these SARS-CoV-2-specific responses were greater in magnitude than EBV-specific responses (Figure 4i), and hematologic cancer patients had greater SARS-CoV-2 antigen-specific T cell responses than solid cancer patients (Extended Data Fig 10c).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel i",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel c",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel i",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Moreover, in hematologic cancer patients who recovered from COVID-19, SARS-CoV-2-specific IFN-γ responses correlated with the frequency of HLA-DR+CD38+ CD8 T cells (Fig 4k), but not with HLA-DR+CD38+ CD4 T cells (Extended Data 10d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel k",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel k",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel k",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "This correlation was not seen in patients who died (Extended Data Fig 10e).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "Panel e",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Results are expressed in Spot Forming Units (SFU) per 10^6 PBMCs.Extended Data\nExtended Data Fig. 1 |.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Repeat SARS-CoV-2 RT-PCR testing results (c) from first positive test to last performed test and (d) from first positive test to last positive test. (All) Significance determined by two-sided Mann Whitney test.Extended Data Fig. 2 |.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 3 |.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\n(a) UMAP projections of lymphocytes with indicated protein expression. (b) Frequencies of CD19+, CD3+, CD3+CD8+, and CD3+CD4+ cells of patients in each EMD cluster (Cluster 1 n=7; Cluster 2 n=16; Cluster 3 n=6; Cluster 4 n=10; Cluster 5 n=5). (All) Median and 95% CI shown.Extended Data Fig. 4 |.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 5 |.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 6 |.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\n(a) UMAP projections of lymphocytes with indicated protein expression. (b) Absolute counts of CD19+, CD3+, CD3+CD8+, and CD3+CD4+ cells of patients in each EMD cluster (Cluster 1 n=18; Cluster 2 n=6; Cluster 4 n=26; Cluster 5 n=7). (All) Median and 95% CI shown.Extended Data Fig. 7 |.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 8 |.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 9 |.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 10 |.",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Current or prior smoking (p = 0.028), poor ECOG performance (ECOG 3–4, p=0.001), and active cancer status (p=0.024) (Fig. 1) were all associated with increased COVID-19 mortality.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Similar results were observed in time-to-event analyses using Kaplan Meier methods (Fig. 2a, median overall survival (mOS) not reached for patients with solid cancers vs 47 days for patients with hematologic cancers, p-value=0.030) and Cox regression models (Table 2, HR 2.56, 95% CI 1.19–5.54, p=0.017).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Moreover, patients with hematologic cancers had higher levels of some inflammatory markers on admission laboratory testing, including ferritin, IL-6, and LDH (Fig. 2b, Extended Data Fig. 1a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Both hematologic and solid cancer patients had prolonged viral clearance, with some greater than 60 days (Extended Data Figure 1c,d, Supplemental Table 3).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel c",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Patients with active cancer were older and predominantly female; both groups had a similar timeframe of symptom onset and disease severity (Fig. 3a, Supplemental Table 4).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel a",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "However, cancer patients had a higher all-cause mortality (36.4% versus 11.1%, Fig. 3a), consistent with our COPE cohort and other reported cohorts21, 24,27,28.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel a",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Cancer patients had significantly decreased SARS-CoV-2-specific IgG and IgM antibodies compared to non-cancer patients (Extended Data Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This was largely due to hematologic cancer patients, the majority (6/7) of whom had IgM and IgG levels below the cutoff of positivity of 0.48 arbitrary units (Fig. 3b, Extended Data Fig. 2b), while those with solid cancers had IgG and IgM antibody responses that were more comparable to patients without cancer (Fig. 3b).T cell-depleted phenotype associated with COVID-19 mortality\nPatients who recover from COVID-19 also exhibit SARS-CoV-2-specific CD4 and CD8 T cell responses43,44.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "UMAP (Uniform Manifold Approximation and Projection) representation of 27-parameter flow cytometry data highlighted discrete islands of CD4 and CD8 T cells, and CD19+ B cells (Fig. 3c and Extended Data Fig. 3a).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel a",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Clustering on EMD values identified 5 clusters of patients with similar lymphocyte profiles (Fig. 3c).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Differences between these clusters of patients were driven by both the distribution (Fig. 3d and Extended Data Fig. 3b) and phenotype (Fig. 3e) of CD4, CD8, and B cells.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel d",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "EMD cluster 1 was defined by depleted CD4 and B cells, increased CD8 T cells, and increased activation and effector markers, including PD-1, CX3CR1, Ki67, and HLA-DR (Fig. 3 d,e and Extended Data Fig. 3b).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In contrast, EMD cluster 4 was defined by robust CCR7+CD27+ memory CD4 T cell responses and heterogenous B cell responses; EMD cluster 2 had the most balanced responses, with CD4, CD8, and B cells represented (Fig. 3d,e and Extended Data Fig. 3b).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel d",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "EMD cluster 5 patients with depleted T cells had the highest mortality and disease severity, despite generating SARS-CoV-2-specific IgM and IgG antibodies (Fig. 3f, Extended Data Fig. 5d).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel f",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel d",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "In contrast, EMD clusters 2 and 4, with robust CD4 and/or CD8 T cell responses, had the lowest mortality and a low disease severity (Fig. 3f, Extended Data Fig. 5d).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel f",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel d",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Four out of the 6 solid cancer patients were in EMD cluster 2, with a balanced immune phenotype (Fig. 3e).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Indeed, UMAP projections showed that while solid cancer patients had an immune landscape similar to non-cancer patients, the two hematologic cancer patients demonstrated loss of islands associated with CD4 and B cells (Fig. 3g).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel g",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel g",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel g",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "COVID-19 patients with hematologic cancers had a significantly lower frequency of CD4 and B cells compared to solid cancer patients, non-cancer patients, and healthy donors without COVID-19 (Fig. 3h).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel h",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel h",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel h",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Although limited by sample size, patients with hematologic cancers had low circulating Tfh (PD1+ CXCR5+) and plasmablast responses (CD19+CD27hiCD38hi) and decreased CD138 expression (Extended Data Fig. 4a).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "UMAP clearly separated CX3CR1 and Tbet expressing effector cells from memory CD8 T cells expressing CD27 and TCF-1 (Extended Data Fig. 4b and Fig. 3i).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel b",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel i",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Activated cells, characterized by high HLA-DR, CD38, and Ki67 expression, were identified in clusters 3, 4, and 5 (Extended Data Fig. 4c).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel c",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "CD8 T cell subsets including central memory, effector memory, transitional memory and TEMRA, were similar between patients with and without cancer (Extended Data Fig. 4d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel d",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "However, UMAP representation of non-naïve CD8 data demonstrated preferential enrichment of cells expressing HLA-DR and CD38 in cancer patients compared to non-cancer patients (Fig. 3j).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel j",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel j",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel j",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Indeed, cancer patients had higher frequencies of activated HLA-DR, CD38, and Ki67-expressing FlowSOM clusters (clusters 3, 4, and 5) compared to non-cancer patients and healthy donors (Fig. 3k and Extended Data Fig. 4e).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel k",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel e",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "When stratified by cancer type, the increased HLA-DR and CD38 expression was restricted to the patients with hematologic cancers; patients with solid cancers and those without cancer had comparable levels of activation (Fig. 3l).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel l",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel l",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel l",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The median age of the MSKCC cohort was 65 years, and in contrast to the MESSI cohort at Penn, 81% of the cohort was white (Fig. 4a, Supplemental Table 7,8).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Consistent with the Penn COPE and MESSI cohorts, patients with hematologic cancers did poorly, with a mortality rate of 44.4% (Fig. 4a, Supplemental Table 7).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In the MSKCC cohort, both CD4 and CD8 T cells were significantly decreased in patients with active solid and hematologic cancers, compared with patients in clinical remission (Extended Data Fig. 5a).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel a",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Moreover, despite the fact that a substantial number of patients with hematologic cancers from the MSKCC cohort received convalescent plasma (Supplemental Table 7), they had a significant defect in SARS-CoV-2-specific IgG and IgM responses as compared to solid cancers (Extended Data Fig. 5b).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel b",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "This was independent of disease severity and viral load (Extended Data Fig. 5c,d).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel c",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.EMD and clustering of flow cytometry data from 20 solid cancer, 31 hematologic cancer, and 6 remission patients identified 4 immune phenotypes (Fig. 4b,c and Extended Data Fig. 6a,b) that corresponded to the immune phenotypes 1,2,4, and 5 identified in the Penn-MESSI cohort (Fig. 3c,d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel b",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel a",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Consistent with the Penn data, MSKCC EMD cluster 5, with depleted of CD4 and CD8 T cells and preserved B cells, had the highest mortality of 71%, and was associated with a high disease severity and viral load (Fig 4d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel d",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel d",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel d",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Solid cancer patients in the MSKCC cohort were present in all 4 clusters, with a majority in cluster 4, while hematologic cancer patients were predominantly in clusters 1 and 4 and absent from cluster 2 (Extended Data Figure 7a and b).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel a",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Hematologic cancer patients with phenotype 4 had a mortality of 62% versus 9% in patients with solid cancers (Extended Data Fig. 7c), with a corresponding higher viral load (Extended Data Fig. 7d).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel c",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel d",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Immune phenotype 4 was characterized by robust CD4 responses and decreased, but still present, CD8 responses (Extended Data Fig 6b).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel b",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Within immune phenotype 4, patients with solid and hematologic cancers had similar CD4 and CD8 T cell counts (Extended Data Figure 7e).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel e",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "However, patients with hematologic cancers had near-complete abrogation of B cells (phenotype 4A) that corresponded with a mortality rate of 62% (Extended Fig 7c and f).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel c",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "In contrast, patients with solid cancers had intact B cells counts (phenotype 4B) with a mortality of 9% (Extended Data Fig 7c and f).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel c",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Anti-CD20 therapy (αCD20) with rituximab or obinutuzumab-containing regimens depleted circulating B cells and significantly impaired SARS-CoV-2-specific IgG and IgM responses (Fig. 4e, Extended Data Fig. 8a). αCD20 was not associated with quantitative changes in CD4 and CD8 T cells.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel e",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel a",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "However, patients treated with anti-CD20 therapy exhibited significant reductions in CD4 and CD8 naïve and memory T cells, with a relative skewing towards effector differentiation and an activated HLA-DR+CD38+ phenotype (Extended Data Fig. 8b,c).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel b",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "These changes were not seen in αCD20-treated hematologic patients without COVID-19 (Extended Data Fig. 8d,e).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel d",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Importantly, despite the loss of B cells and humoral immunity, αCD20 therapy was not associated with increased mortality, disease severity, or viral load when compared to chemotherapy or observation (Extended Data Fig. 9a).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel a",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Patients treated with αCD20 therapy were restricted to immune phenotypes 1 and 4, characterized by depleted B cells (Extended Data Fig. 9b).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel b",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "However, phenotype 1, characterized by preserved CD8 T cells, was associated with a lower mortality (Extended Data Fig. 9c).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel c",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Indeed, αCD20 treated patients who survived their COVID-19 hospitalization had higher CD8 T cell counts (Fig 4f), and lower viral load (Extended Data Fig. 9d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel f",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel d",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel f",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel f",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "We extended these analyses to other patients with hematologic cancers, including those on chemotherapy who also had quantitative (Extended Data Fig. 8a), and possibly qualitative B cell defects.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel a",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Hematologic cancer patients who survived had higher CD8 T cell count (Fig. 4g), which was not observed in solid cancer patients (Extended Data Fig. 9e).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel g",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel e",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel g",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel g",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Conversely, CD4 T cell counts were not associated with mortality, and higher B cell counts were associated with increased mortality (Extended Data Fig. 9e, Fig 4g).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel e",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel g",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Classification and Regression Tree Analysis (CART) identified a CD8 T cell level that was predictive of survival after COVID-19 in patients with hematologic cancers (Fig. 4h).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel h",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel h",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel h",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Finally, to assess the antigen-specificity of T cell responses in SARS-CoV-2 infected cancer patients, we stimulated PBMC from 13 hematologic cancer patients and 10 solid cancer patients using MHC-I and MHC-II restricted SARS-CoV-2 and EBV peptide pools and measured IFN-γ and IL-2 responses using ELISpot (Extended Data Figure 10a).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "Panel a",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "After background (no-peptide) subtraction, 10 out of 13 (77%) of hematologic cancer patients had SARS-CoV-2- specific IL-2 and/or IFN-γ responses (Figure 4i), including 8 out of 8 (100%) of patients treated with αCD20 (Figure 4j, Extended Data Fig 10b).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel i",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel j",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel b",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel i",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In general, these SARS-CoV-2-specific responses were greater in magnitude than EBV-specific responses (Figure 4i), and hematologic cancer patients had greater SARS-CoV-2 antigen-specific T cell responses than solid cancer patients (Extended Data Fig 10c).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel i",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel c",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel i",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Moreover, in hematologic cancer patients who recovered from COVID-19, SARS-CoV-2-specific IFN-γ responses correlated with the frequency of HLA-DR+CD38+ CD8 T cells (Fig 4k), but not with HLA-DR+CD38+ CD4 T cells (Extended Data 10d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel k",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel k",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel k",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "This correlation was not seen in patients who died (Extended Data Fig 10e).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "Panel e",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Results are expressed in Spot Forming Units (SFU) per 10^6 PBMCs.Extended Data\nExtended Data Fig. 1 |.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Repeat SARS-CoV-2 RT-PCR testing results (c) from first positive test to last performed test and (d) from first positive test to last positive test. (All) Significance determined by two-sided Mann Whitney test.Extended Data Fig. 2 |.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 3 |.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\n(a) UMAP projections of lymphocytes with indicated protein expression. (b) Frequencies of CD19+, CD3+, CD3+CD8+, and CD3+CD4+ cells of patients in each EMD cluster (Cluster 1 n=7; Cluster 2 n=16; Cluster 3 n=6; Cluster 4 n=10; Cluster 5 n=5). (All) Median and 95% CI shown.Extended Data Fig. 4 |.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 5 |.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 6 |.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\n(a) UMAP projections of lymphocytes with indicated protein expression. (b) Absolute counts of CD19+, CD3+, CD3+CD8+, and CD3+CD4+ cells of patients in each EMD cluster (Cluster 1 n=18; Cluster 2 n=6; Cluster 4 n=26; Cluster 5 n=7). (All) Median and 95% CI shown.Extended Data Fig. 7 |.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 8 |.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 9 |.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 10 |.",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Current or prior smoking (p = 0.028), poor ECOG performance (ECOG 3–4, p=0.001), and active cancer status (p=0.024) (Fig. 1) were all associated with increased COVID-19 mortality.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Similar results were observed in time-to-event analyses using Kaplan Meier methods (Fig. 2a, median overall survival (mOS) not reached for patients with solid cancers vs 47 days for patients with hematologic cancers, p-value=0.030) and Cox regression models (Table 2, HR 2.56, 95% CI 1.19–5.54, p=0.017).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Moreover, patients with hematologic cancers had higher levels of some inflammatory markers on admission laboratory testing, including ferritin, IL-6, and LDH (Fig. 2b, Extended Data Fig. 1a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Both hematologic and solid cancer patients had prolonged viral clearance, with some greater than 60 days (Extended Data Figure 1c,d, Supplemental Table 3).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel c",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Patients with active cancer were older and predominantly female; both groups had a similar timeframe of symptom onset and disease severity (Fig. 3a, Supplemental Table 4).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel a",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "However, cancer patients had a higher all-cause mortality (36.4% versus 11.1%, Fig. 3a), consistent with our COPE cohort and other reported cohorts21, 24,27,28.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel a",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Cancer patients had significantly decreased SARS-CoV-2-specific IgG and IgM antibodies compared to non-cancer patients (Extended Data Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This was largely due to hematologic cancer patients, the majority (6/7) of whom had IgM and IgG levels below the cutoff of positivity of 0.48 arbitrary units (Fig. 3b, Extended Data Fig. 2b), while those with solid cancers had IgG and IgM antibody responses that were more comparable to patients without cancer (Fig. 3b).T cell-depleted phenotype associated with COVID-19 mortality\nPatients who recover from COVID-19 also exhibit SARS-CoV-2-specific CD4 and CD8 T cell responses43,44.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "UMAP (Uniform Manifold Approximation and Projection) representation of 27-parameter flow cytometry data highlighted discrete islands of CD4 and CD8 T cells, and CD19+ B cells (Fig. 3c and Extended Data Fig. 3a).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel a",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Clustering on EMD values identified 5 clusters of patients with similar lymphocyte profiles (Fig. 3c).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Differences between these clusters of patients were driven by both the distribution (Fig. 3d and Extended Data Fig. 3b) and phenotype (Fig. 3e) of CD4, CD8, and B cells.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel d",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "EMD cluster 1 was defined by depleted CD4 and B cells, increased CD8 T cells, and increased activation and effector markers, including PD-1, CX3CR1, Ki67, and HLA-DR (Fig. 3 d,e and Extended Data Fig. 3b).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In contrast, EMD cluster 4 was defined by robust CCR7+CD27+ memory CD4 T cell responses and heterogenous B cell responses; EMD cluster 2 had the most balanced responses, with CD4, CD8, and B cells represented (Fig. 3d,e and Extended Data Fig. 3b).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel d",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "EMD cluster 5 patients with depleted T cells had the highest mortality and disease severity, despite generating SARS-CoV-2-specific IgM and IgG antibodies (Fig. 3f, Extended Data Fig. 5d).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel f",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel d",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "In contrast, EMD clusters 2 and 4, with robust CD4 and/or CD8 T cell responses, had the lowest mortality and a low disease severity (Fig. 3f, Extended Data Fig. 5d).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel f",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel d",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Four out of the 6 solid cancer patients were in EMD cluster 2, with a balanced immune phenotype (Fig. 3e).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Indeed, UMAP projections showed that while solid cancer patients had an immune landscape similar to non-cancer patients, the two hematologic cancer patients demonstrated loss of islands associated with CD4 and B cells (Fig. 3g).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel g",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel g",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel g",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "COVID-19 patients with hematologic cancers had a significantly lower frequency of CD4 and B cells compared to solid cancer patients, non-cancer patients, and healthy donors without COVID-19 (Fig. 3h).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel h",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel h",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel h",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Although limited by sample size, patients with hematologic cancers had low circulating Tfh (PD1+ CXCR5+) and plasmablast responses (CD19+CD27hiCD38hi) and decreased CD138 expression (Extended Data Fig. 4a).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "UMAP clearly separated CX3CR1 and Tbet expressing effector cells from memory CD8 T cells expressing CD27 and TCF-1 (Extended Data Fig. 4b and Fig. 3i).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel b",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel i",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Activated cells, characterized by high HLA-DR, CD38, and Ki67 expression, were identified in clusters 3, 4, and 5 (Extended Data Fig. 4c).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel c",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "CD8 T cell subsets including central memory, effector memory, transitional memory and TEMRA, were similar between patients with and without cancer (Extended Data Fig. 4d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel d",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "However, UMAP representation of non-naïve CD8 data demonstrated preferential enrichment of cells expressing HLA-DR and CD38 in cancer patients compared to non-cancer patients (Fig. 3j).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel j",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel j",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel j",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Indeed, cancer patients had higher frequencies of activated HLA-DR, CD38, and Ki67-expressing FlowSOM clusters (clusters 3, 4, and 5) compared to non-cancer patients and healthy donors (Fig. 3k and Extended Data Fig. 4e).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel k",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel e",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "When stratified by cancer type, the increased HLA-DR and CD38 expression was restricted to the patients with hematologic cancers; patients with solid cancers and those without cancer had comparable levels of activation (Fig. 3l).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel l",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel l",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel l",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The median age of the MSKCC cohort was 65 years, and in contrast to the MESSI cohort at Penn, 81% of the cohort was white (Fig. 4a, Supplemental Table 7,8).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Consistent with the Penn COPE and MESSI cohorts, patients with hematologic cancers did poorly, with a mortality rate of 44.4% (Fig. 4a, Supplemental Table 7).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In the MSKCC cohort, both CD4 and CD8 T cells were significantly decreased in patients with active solid and hematologic cancers, compared with patients in clinical remission (Extended Data Fig. 5a).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel a",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Moreover, despite the fact that a substantial number of patients with hematologic cancers from the MSKCC cohort received convalescent plasma (Supplemental Table 7), they had a significant defect in SARS-CoV-2-specific IgG and IgM responses as compared to solid cancers (Extended Data Fig. 5b).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel b",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "This was independent of disease severity and viral load (Extended Data Fig. 5c,d).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel c",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.EMD and clustering of flow cytometry data from 20 solid cancer, 31 hematologic cancer, and 6 remission patients identified 4 immune phenotypes (Fig. 4b,c and Extended Data Fig. 6a,b) that corresponded to the immune phenotypes 1,2,4, and 5 identified in the Penn-MESSI cohort (Fig. 3c,d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel b",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel a",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Consistent with the Penn data, MSKCC EMD cluster 5, with depleted of CD4 and CD8 T cells and preserved B cells, had the highest mortality of 71%, and was associated with a high disease severity and viral load (Fig 4d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel d",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel d",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel d",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Solid cancer patients in the MSKCC cohort were present in all 4 clusters, with a majority in cluster 4, while hematologic cancer patients were predominantly in clusters 1 and 4 and absent from cluster 2 (Extended Data Figure 7a and b).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel a",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Hematologic cancer patients with phenotype 4 had a mortality of 62% versus 9% in patients with solid cancers (Extended Data Fig. 7c), with a corresponding higher viral load (Extended Data Fig. 7d).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel c",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel d",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Immune phenotype 4 was characterized by robust CD4 responses and decreased, but still present, CD8 responses (Extended Data Fig 6b).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel b",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Within immune phenotype 4, patients with solid and hematologic cancers had similar CD4 and CD8 T cell counts (Extended Data Figure 7e).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel e",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "However, patients with hematologic cancers had near-complete abrogation of B cells (phenotype 4A) that corresponded with a mortality rate of 62% (Extended Fig 7c and f).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel c",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "In contrast, patients with solid cancers had intact B cells counts (phenotype 4B) with a mortality of 9% (Extended Data Fig 7c and f).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel c",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Anti-CD20 therapy (αCD20) with rituximab or obinutuzumab-containing regimens depleted circulating B cells and significantly impaired SARS-CoV-2-specific IgG and IgM responses (Fig. 4e, Extended Data Fig. 8a). αCD20 was not associated with quantitative changes in CD4 and CD8 T cells.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel e",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel a",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "However, patients treated with anti-CD20 therapy exhibited significant reductions in CD4 and CD8 naïve and memory T cells, with a relative skewing towards effector differentiation and an activated HLA-DR+CD38+ phenotype (Extended Data Fig. 8b,c).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel b",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "These changes were not seen in αCD20-treated hematologic patients without COVID-19 (Extended Data Fig. 8d,e).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel d",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Importantly, despite the loss of B cells and humoral immunity, αCD20 therapy was not associated with increased mortality, disease severity, or viral load when compared to chemotherapy or observation (Extended Data Fig. 9a).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel a",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Patients treated with αCD20 therapy were restricted to immune phenotypes 1 and 4, characterized by depleted B cells (Extended Data Fig. 9b).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel b",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "However, phenotype 1, characterized by preserved CD8 T cells, was associated with a lower mortality (Extended Data Fig. 9c).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel c",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Indeed, αCD20 treated patients who survived their COVID-19 hospitalization had higher CD8 T cell counts (Fig 4f), and lower viral load (Extended Data Fig. 9d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel f",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel d",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel f",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel f",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "We extended these analyses to other patients with hematologic cancers, including those on chemotherapy who also had quantitative (Extended Data Fig. 8a), and possibly qualitative B cell defects.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel a",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Hematologic cancer patients who survived had higher CD8 T cell count (Fig. 4g), which was not observed in solid cancer patients (Extended Data Fig. 9e).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel g",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel e",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel g",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel g",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Conversely, CD4 T cell counts were not associated with mortality, and higher B cell counts were associated with increased mortality (Extended Data Fig. 9e, Fig 4g).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel e",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel g",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Classification and Regression Tree Analysis (CART) identified a CD8 T cell level that was predictive of survival after COVID-19 in patients with hematologic cancers (Fig. 4h).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel h",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel h",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel h",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Finally, to assess the antigen-specificity of T cell responses in SARS-CoV-2 infected cancer patients, we stimulated PBMC from 13 hematologic cancer patients and 10 solid cancer patients using MHC-I and MHC-II restricted SARS-CoV-2 and EBV peptide pools and measured IFN-γ and IL-2 responses using ELISpot (Extended Data Figure 10a).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "Panel a",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "After background (no-peptide) subtraction, 10 out of 13 (77%) of hematologic cancer patients had SARS-CoV-2- specific IL-2 and/or IFN-γ responses (Figure 4i), including 8 out of 8 (100%) of patients treated with αCD20 (Figure 4j, Extended Data Fig 10b).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel i",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel j",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel b",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel i",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In general, these SARS-CoV-2-specific responses were greater in magnitude than EBV-specific responses (Figure 4i), and hematologic cancer patients had greater SARS-CoV-2 antigen-specific T cell responses than solid cancer patients (Extended Data Fig 10c).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel i",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel c",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel i",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Moreover, in hematologic cancer patients who recovered from COVID-19, SARS-CoV-2-specific IFN-γ responses correlated with the frequency of HLA-DR+CD38+ CD8 T cells (Fig 4k), but not with HLA-DR+CD38+ CD4 T cells (Extended Data 10d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel k",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel k",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel k",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "This correlation was not seen in patients who died (Extended Data Fig 10e).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "Panel e",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Current or prior smoking (p = 0.028), poor ECOG performance (ECOG 3–4, p=0.001), and active cancer status (p=0.024) (Fig. 1) were all associated with increased COVID-19 mortality.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Similar results were observed in time-to-event analyses using Kaplan Meier methods (Fig. 2a, median overall survival (mOS) not reached for patients with solid cancers vs 47 days for patients with hematologic cancers, p-value=0.030) and Cox regression models (Table 2, HR 2.56, 95% CI 1.19–5.54, p=0.017).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Moreover, patients with hematologic cancers had higher levels of some inflammatory markers on admission laboratory testing, including ferritin, IL-6, and LDH (Fig. 2b, Extended Data Fig. 1a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Both hematologic and solid cancer patients had prolonged viral clearance, with some greater than 60 days (Extended Data Figure 1c,d, Supplemental Table 3).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel c",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Current or prior smoking (p = 0.028), poor ECOG performance (ECOG 3–4, p=0.001), and active cancer status (p=0.024) (Fig. 1) were all associated with increased COVID-19 mortality.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Similar results were observed in time-to-event analyses using Kaplan Meier methods (Fig. 2a, median overall survival (mOS) not reached for patients with solid cancers vs 47 days for patients with hematologic cancers, p-value=0.030) and Cox regression models (Table 2, HR 2.56, 95% CI 1.19–5.54, p=0.017).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Moreover, patients with hematologic cancers had higher levels of some inflammatory markers on admission laboratory testing, including ferritin, IL-6, and LDH (Fig. 2b, Extended Data Fig. 1a,b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Both hematologic and solid cancer patients had prolonged viral clearance, with some greater than 60 days (Extended Data Figure 1c,d, Supplemental Table 3).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel c",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Patients with active cancer were older and predominantly female; both groups had a similar timeframe of symptom onset and disease severity (Fig. 3a, Supplemental Table 4).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel a",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "However, cancer patients had a higher all-cause mortality (36.4% versus 11.1%, Fig. 3a), consistent with our COPE cohort and other reported cohorts21, 24,27,28.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel a",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Cancer patients had significantly decreased SARS-CoV-2-specific IgG and IgM antibodies compared to non-cancer patients (Extended Data Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This was largely due to hematologic cancer patients, the majority (6/7) of whom had IgM and IgG levels below the cutoff of positivity of 0.48 arbitrary units (Fig. 3b, Extended Data Fig. 2b), while those with solid cancers had IgG and IgM antibody responses that were more comparable to patients without cancer (Fig. 3b).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Patients with active cancer were older and predominantly female; both groups had a similar timeframe of symptom onset and disease severity (Fig. 3a, Supplemental Table 4).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel a",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "However, cancer patients had a higher all-cause mortality (36.4% versus 11.1%, Fig. 3a), consistent with our COPE cohort and other reported cohorts21, 24,27,28.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel a",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Cancer patients had significantly decreased SARS-CoV-2-specific IgG and IgM antibodies compared to non-cancer patients (Extended Data Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This was largely due to hematologic cancer patients, the majority (6/7) of whom had IgM and IgG levels below the cutoff of positivity of 0.48 arbitrary units (Fig. 3b, Extended Data Fig. 2b), while those with solid cancers had IgG and IgM antibody responses that were more comparable to patients without cancer (Fig. 3b).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "UMAP (Uniform Manifold Approximation and Projection) representation of 27-parameter flow cytometry data highlighted discrete islands of CD4 and CD8 T cells, and CD19+ B cells (Fig. 3c and Extended Data Fig. 3a).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel a",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Clustering on EMD values identified 5 clusters of patients with similar lymphocyte profiles (Fig. 3c).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Differences between these clusters of patients were driven by both the distribution (Fig. 3d and Extended Data Fig. 3b) and phenotype (Fig. 3e) of CD4, CD8, and B cells.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel d",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "EMD cluster 1 was defined by depleted CD4 and B cells, increased CD8 T cells, and increased activation and effector markers, including PD-1, CX3CR1, Ki67, and HLA-DR (Fig. 3 d,e and Extended Data Fig. 3b).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In contrast, EMD cluster 4 was defined by robust CCR7+CD27+ memory CD4 T cell responses and heterogenous B cell responses; EMD cluster 2 had the most balanced responses, with CD4, CD8, and B cells represented (Fig. 3d,e and Extended Data Fig. 3b).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel d",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "EMD cluster 5 patients with depleted T cells had the highest mortality and disease severity, despite generating SARS-CoV-2-specific IgM and IgG antibodies (Fig. 3f, Extended Data Fig. 5d).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel f",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel d",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "In contrast, EMD clusters 2 and 4, with robust CD4 and/or CD8 T cell responses, had the lowest mortality and a low disease severity (Fig. 3f, Extended Data Fig. 5d).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel f",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel d",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "UMAP (Uniform Manifold Approximation and Projection) representation of 27-parameter flow cytometry data highlighted discrete islands of CD4 and CD8 T cells, and CD19+ B cells (Fig. 3c and Extended Data Fig. 3a).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel a",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Clustering on EMD values identified 5 clusters of patients with similar lymphocyte profiles (Fig. 3c).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Differences between these clusters of patients were driven by both the distribution (Fig. 3d and Extended Data Fig. 3b) and phenotype (Fig. 3e) of CD4, CD8, and B cells.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel d",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "EMD cluster 1 was defined by depleted CD4 and B cells, increased CD8 T cells, and increased activation and effector markers, including PD-1, CX3CR1, Ki67, and HLA-DR (Fig. 3 d,e and Extended Data Fig. 3b).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In contrast, EMD cluster 4 was defined by robust CCR7+CD27+ memory CD4 T cell responses and heterogenous B cell responses; EMD cluster 2 had the most balanced responses, with CD4, CD8, and B cells represented (Fig. 3d,e and Extended Data Fig. 3b).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel d",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "EMD cluster 5 patients with depleted T cells had the highest mortality and disease severity, despite generating SARS-CoV-2-specific IgM and IgG antibodies (Fig. 3f, Extended Data Fig. 5d).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel f",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel d",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "In contrast, EMD clusters 2 and 4, with robust CD4 and/or CD8 T cell responses, had the lowest mortality and a low disease severity (Fig. 3f, Extended Data Fig. 5d).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel f",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel d",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Four out of the 6 solid cancer patients were in EMD cluster 2, with a balanced immune phenotype (Fig. 3e).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Indeed, UMAP projections showed that while solid cancer patients had an immune landscape similar to non-cancer patients, the two hematologic cancer patients demonstrated loss of islands associated with CD4 and B cells (Fig. 3g).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel g",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel g",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel g",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "COVID-19 patients with hematologic cancers had a significantly lower frequency of CD4 and B cells compared to solid cancer patients, non-cancer patients, and healthy donors without COVID-19 (Fig. 3h).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel h",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel h",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel h",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Although limited by sample size, patients with hematologic cancers had low circulating Tfh (PD1+ CXCR5+) and plasmablast responses (CD19+CD27hiCD38hi) and decreased CD138 expression (Extended Data Fig. 4a).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "UMAP clearly separated CX3CR1 and Tbet expressing effector cells from memory CD8 T cells expressing CD27 and TCF-1 (Extended Data Fig. 4b and Fig. 3i).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel b",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel i",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Activated cells, characterized by high HLA-DR, CD38, and Ki67 expression, were identified in clusters 3, 4, and 5 (Extended Data Fig. 4c).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel c",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "CD8 T cell subsets including central memory, effector memory, transitional memory and TEMRA, were similar between patients with and without cancer (Extended Data Fig. 4d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel d",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "However, UMAP representation of non-naïve CD8 data demonstrated preferential enrichment of cells expressing HLA-DR and CD38 in cancer patients compared to non-cancer patients (Fig. 3j).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel j",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel j",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel j",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Indeed, cancer patients had higher frequencies of activated HLA-DR, CD38, and Ki67-expressing FlowSOM clusters (clusters 3, 4, and 5) compared to non-cancer patients and healthy donors (Fig. 3k and Extended Data Fig. 4e).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel k",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel e",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "When stratified by cancer type, the increased HLA-DR and CD38 expression was restricted to the patients with hematologic cancers; patients with solid cancers and those without cancer had comparable levels of activation (Fig. 3l).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel l",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel l",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel l",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Four out of the 6 solid cancer patients were in EMD cluster 2, with a balanced immune phenotype (Fig. 3e).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Indeed, UMAP projections showed that while solid cancer patients had an immune landscape similar to non-cancer patients, the two hematologic cancer patients demonstrated loss of islands associated with CD4 and B cells (Fig. 3g).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel g",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel g",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel g",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "COVID-19 patients with hematologic cancers had a significantly lower frequency of CD4 and B cells compared to solid cancer patients, non-cancer patients, and healthy donors without COVID-19 (Fig. 3h).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel h",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel h",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel h",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Although limited by sample size, patients with hematologic cancers had low circulating Tfh (PD1+ CXCR5+) and plasmablast responses (CD19+CD27hiCD38hi) and decreased CD138 expression (Extended Data Fig. 4a).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "UMAP clearly separated CX3CR1 and Tbet expressing effector cells from memory CD8 T cells expressing CD27 and TCF-1 (Extended Data Fig. 4b and Fig. 3i).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel b",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel i",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Activated cells, characterized by high HLA-DR, CD38, and Ki67 expression, were identified in clusters 3, 4, and 5 (Extended Data Fig. 4c).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel c",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "CD8 T cell subsets including central memory, effector memory, transitional memory and TEMRA, were similar between patients with and without cancer (Extended Data Fig. 4d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel d",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "However, UMAP representation of non-naïve CD8 data demonstrated preferential enrichment of cells expressing HLA-DR and CD38 in cancer patients compared to non-cancer patients (Fig. 3j).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel j",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel j",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel j",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Indeed, cancer patients had higher frequencies of activated HLA-DR, CD38, and Ki67-expressing FlowSOM clusters (clusters 3, 4, and 5) compared to non-cancer patients and healthy donors (Fig. 3k and Extended Data Fig. 4e).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel k",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel e",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "When stratified by cancer type, the increased HLA-DR and CD38 expression was restricted to the patients with hematologic cancers; patients with solid cancers and those without cancer had comparable levels of activation (Fig. 3l).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel l",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel l",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel l",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The median age of the MSKCC cohort was 65 years, and in contrast to the MESSI cohort at Penn, 81% of the cohort was white (Fig. 4a, Supplemental Table 7,8).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Consistent with the Penn COPE and MESSI cohorts, patients with hematologic cancers did poorly, with a mortality rate of 44.4% (Fig. 4a, Supplemental Table 7).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In the MSKCC cohort, both CD4 and CD8 T cells were significantly decreased in patients with active solid and hematologic cancers, compared with patients in clinical remission (Extended Data Fig. 5a).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel a",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Moreover, despite the fact that a substantial number of patients with hematologic cancers from the MSKCC cohort received convalescent plasma (Supplemental Table 7), they had a significant defect in SARS-CoV-2-specific IgG and IgM responses as compared to solid cancers (Extended Data Fig. 5b).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel b",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "This was independent of disease severity and viral load (Extended Data Fig. 5c,d).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel c",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.EMD and clustering of flow cytometry data from 20 solid cancer, 31 hematologic cancer, and 6 remission patients identified 4 immune phenotypes (Fig. 4b,c and Extended Data Fig. 6a,b) that corresponded to the immune phenotypes 1,2,4, and 5 identified in the Penn-MESSI cohort (Fig. 3c,d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel b",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel a",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Consistent with the Penn data, MSKCC EMD cluster 5, with depleted of CD4 and CD8 T cells and preserved B cells, had the highest mortality of 71%, and was associated with a high disease severity and viral load (Fig 4d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel d",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel d",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel d",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Solid cancer patients in the MSKCC cohort were present in all 4 clusters, with a majority in cluster 4, while hematologic cancer patients were predominantly in clusters 1 and 4 and absent from cluster 2 (Extended Data Figure 7a and b).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel a",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Hematologic cancer patients with phenotype 4 had a mortality of 62% versus 9% in patients with solid cancers (Extended Data Fig. 7c), with a corresponding higher viral load (Extended Data Fig. 7d).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel c",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel d",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Immune phenotype 4 was characterized by robust CD4 responses and decreased, but still present, CD8 responses (Extended Data Fig 6b).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel b",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Within immune phenotype 4, patients with solid and hematologic cancers had similar CD4 and CD8 T cell counts (Extended Data Figure 7e).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel e",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "However, patients with hematologic cancers had near-complete abrogation of B cells (phenotype 4A) that corresponded with a mortality rate of 62% (Extended Fig 7c and f).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel c",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "In contrast, patients with solid cancers had intact B cells counts (phenotype 4B) with a mortality of 9% (Extended Data Fig 7c and f).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel c",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Anti-CD20 therapy (αCD20) with rituximab or obinutuzumab-containing regimens depleted circulating B cells and significantly impaired SARS-CoV-2-specific IgG and IgM responses (Fig. 4e, Extended Data Fig. 8a). αCD20 was not associated with quantitative changes in CD4 and CD8 T cells.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel e",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel a",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "However, patients treated with anti-CD20 therapy exhibited significant reductions in CD4 and CD8 naïve and memory T cells, with a relative skewing towards effector differentiation and an activated HLA-DR+CD38+ phenotype (Extended Data Fig. 8b,c).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel b",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "These changes were not seen in αCD20-treated hematologic patients without COVID-19 (Extended Data Fig. 8d,e).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel d",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Importantly, despite the loss of B cells and humoral immunity, αCD20 therapy was not associated with increased mortality, disease severity, or viral load when compared to chemotherapy or observation (Extended Data Fig. 9a).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel a",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Patients treated with αCD20 therapy were restricted to immune phenotypes 1 and 4, characterized by depleted B cells (Extended Data Fig. 9b).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel b",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "However, phenotype 1, characterized by preserved CD8 T cells, was associated with a lower mortality (Extended Data Fig. 9c).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel c",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Indeed, αCD20 treated patients who survived their COVID-19 hospitalization had higher CD8 T cell counts (Fig 4f), and lower viral load (Extended Data Fig. 9d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel f",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel d",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel f",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel f",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "We extended these analyses to other patients with hematologic cancers, including those on chemotherapy who also had quantitative (Extended Data Fig. 8a), and possibly qualitative B cell defects.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel a",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Hematologic cancer patients who survived had higher CD8 T cell count (Fig. 4g), which was not observed in solid cancer patients (Extended Data Fig. 9e).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel g",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel e",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel g",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel g",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Conversely, CD4 T cell counts were not associated with mortality, and higher B cell counts were associated with increased mortality (Extended Data Fig. 9e, Fig 4g).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel e",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel g",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Classification and Regression Tree Analysis (CART) identified a CD8 T cell level that was predictive of survival after COVID-19 in patients with hematologic cancers (Fig. 4h).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel h",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel h",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel h",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Finally, to assess the antigen-specificity of T cell responses in SARS-CoV-2 infected cancer patients, we stimulated PBMC from 13 hematologic cancer patients and 10 solid cancer patients using MHC-I and MHC-II restricted SARS-CoV-2 and EBV peptide pools and measured IFN-γ and IL-2 responses using ELISpot (Extended Data Figure 10a).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "Panel a",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "After background (no-peptide) subtraction, 10 out of 13 (77%) of hematologic cancer patients had SARS-CoV-2- specific IL-2 and/or IFN-γ responses (Figure 4i), including 8 out of 8 (100%) of patients treated with αCD20 (Figure 4j, Extended Data Fig 10b).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel i",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel j",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel b",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel i",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In general, these SARS-CoV-2-specific responses were greater in magnitude than EBV-specific responses (Figure 4i), and hematologic cancer patients had greater SARS-CoV-2 antigen-specific T cell responses than solid cancer patients (Extended Data Fig 10c).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel i",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel c",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel i",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Moreover, in hematologic cancer patients who recovered from COVID-19, SARS-CoV-2-specific IFN-γ responses correlated with the frequency of HLA-DR+CD38+ CD8 T cells (Fig 4k), but not with HLA-DR+CD38+ CD4 T cells (Extended Data 10d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel k",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel k",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel k",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "This correlation was not seen in patients who died (Extended Data Fig 10e).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "Panel e",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "The median age of the MSKCC cohort was 65 years, and in contrast to the MESSI cohort at Penn, 81% of the cohort was white (Fig. 4a, Supplemental Table 7,8).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Consistent with the Penn COPE and MESSI cohorts, patients with hematologic cancers did poorly, with a mortality rate of 44.4% (Fig. 4a, Supplemental Table 7).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In the MSKCC cohort, both CD4 and CD8 T cells were significantly decreased in patients with active solid and hematologic cancers, compared with patients in clinical remission (Extended Data Fig. 5a).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel a",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Moreover, despite the fact that a substantial number of patients with hematologic cancers from the MSKCC cohort received convalescent plasma (Supplemental Table 7), they had a significant defect in SARS-CoV-2-specific IgG and IgM responses as compared to solid cancers (Extended Data Fig. 5b).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel b",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "This was independent of disease severity and viral load (Extended Data Fig. 5c,d).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel c",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "EMD and clustering of flow cytometry data from 20 solid cancer, 31 hematologic cancer, and 6 remission patients identified 4 immune phenotypes (Fig. 4b,c and Extended Data Fig. 6a,b) that corresponded to the immune phenotypes 1,2,4, and 5 identified in the Penn-MESSI cohort (Fig. 3c,d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel b",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel a",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel c",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Consistent with the Penn data, MSKCC EMD cluster 5, with depleted of CD4 and CD8 T cells and preserved B cells, had the highest mortality of 71%, and was associated with a high disease severity and viral load (Fig 4d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel d",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel d",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel d",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Solid cancer patients in the MSKCC cohort were present in all 4 clusters, with a majority in cluster 4, while hematologic cancer patients were predominantly in clusters 1 and 4 and absent from cluster 2 (Extended Data Figure 7a and b).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel a",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Hematologic cancer patients with phenotype 4 had a mortality of 62% versus 9% in patients with solid cancers (Extended Data Fig. 7c), with a corresponding higher viral load (Extended Data Fig. 7d).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel c",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel d",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Immune phenotype 4 was characterized by robust CD4 responses and decreased, but still present, CD8 responses (Extended Data Fig 6b).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel b",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Within immune phenotype 4, patients with solid and hematologic cancers had similar CD4 and CD8 T cell counts (Extended Data Figure 7e).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel e",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "However, patients with hematologic cancers had near-complete abrogation of B cells (phenotype 4A) that corresponded with a mortality rate of 62% (Extended Fig 7c and f).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel c",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "In contrast, patients with solid cancers had intact B cells counts (phenotype 4B) with a mortality of 9% (Extended Data Fig 7c and f).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel c",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Anti-CD20 therapy (αCD20) with rituximab or obinutuzumab-containing regimens depleted circulating B cells and significantly impaired SARS-CoV-2-specific IgG and IgM responses (Fig. 4e, Extended Data Fig. 8a). αCD20 was not associated with quantitative changes in CD4 and CD8 T cells.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel e",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel a",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "However, patients treated with anti-CD20 therapy exhibited significant reductions in CD4 and CD8 naïve and memory T cells, with a relative skewing towards effector differentiation and an activated HLA-DR+CD38+ phenotype (Extended Data Fig. 8b,c).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel b",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "These changes were not seen in αCD20-treated hematologic patients without COVID-19 (Extended Data Fig. 8d,e).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel d",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Importantly, despite the loss of B cells and humoral immunity, αCD20 therapy was not associated with increased mortality, disease severity, or viral load when compared to chemotherapy or observation (Extended Data Fig. 9a).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel a",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Patients treated with αCD20 therapy were restricted to immune phenotypes 1 and 4, characterized by depleted B cells (Extended Data Fig. 9b).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel b",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "However, phenotype 1, characterized by preserved CD8 T cells, was associated with a lower mortality (Extended Data Fig. 9c).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel c",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Indeed, αCD20 treated patients who survived their COVID-19 hospitalization had higher CD8 T cell counts (Fig 4f), and lower viral load (Extended Data Fig. 9d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel f",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel d",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel f",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel f",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "We extended these analyses to other patients with hematologic cancers, including those on chemotherapy who also had quantitative (Extended Data Fig. 8a), and possibly qualitative B cell defects.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel a",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Hematologic cancer patients who survived had higher CD8 T cell count (Fig. 4g), which was not observed in solid cancer patients (Extended Data Fig. 9e).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel g",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel e",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel g",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel g",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Conversely, CD4 T cell counts were not associated with mortality, and higher B cell counts were associated with increased mortality (Extended Data Fig. 9e, Fig 4g).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel e",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel g",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Classification and Regression Tree Analysis (CART) identified a CD8 T cell level that was predictive of survival after COVID-19 in patients with hematologic cancers (Fig. 4h).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel h",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel h",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel h",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Finally, to assess the antigen-specificity of T cell responses in SARS-CoV-2 infected cancer patients, we stimulated PBMC from 13 hematologic cancer patients and 10 solid cancer patients using MHC-I and MHC-II restricted SARS-CoV-2 and EBV peptide pools and measured IFN-γ and IL-2 responses using ELISpot (Extended Data Figure 10a).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "Panel a",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "After background (no-peptide) subtraction, 10 out of 13 (77%) of hematologic cancer patients had SARS-CoV-2- specific IL-2 and/or IFN-γ responses (Figure 4i), including 8 out of 8 (100%) of patients treated with αCD20 (Figure 4j, Extended Data Fig 10b).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel i",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel j",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel b",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel i",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In general, these SARS-CoV-2-specific responses were greater in magnitude than EBV-specific responses (Figure 4i), and hematologic cancer patients had greater SARS-CoV-2 antigen-specific T cell responses than solid cancer patients (Extended Data Fig 10c).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel i",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel c",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel i",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Moreover, in hematologic cancer patients who recovered from COVID-19, SARS-CoV-2-specific IFN-γ responses correlated with the frequency of HLA-DR+CD38+ CD8 T cells (Fig 4k), but not with HLA-DR+CD38+ CD4 T cells (Extended Data 10d).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel k",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel k",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel k",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "This correlation was not seen in patients who died (Extended Data Fig 10e).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "Panel e",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Extended Data\nExtended Data Fig. 1 |.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Repeat SARS-CoV-2 RT-PCR testing results (c) from first positive test to last performed test and (d) from first positive test to last positive test. (All) Significance determined by two-sided Mann Whitney test.Extended Data Fig. 2 |.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 3 |.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\n(a) UMAP projections of lymphocytes with indicated protein expression. (b) Frequencies of CD19+, CD3+, CD3+CD8+, and CD3+CD4+ cells of patients in each EMD cluster (Cluster 1 n=7; Cluster 2 n=16; Cluster 3 n=6; Cluster 4 n=10; Cluster 5 n=5). (All) Median and 95% CI shown.Extended Data Fig. 4 |.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 5 |.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 6 |.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\n(a) UMAP projections of lymphocytes with indicated protein expression. (b) Absolute counts of CD19+, CD3+, CD3+CD8+, and CD3+CD4+ cells of patients in each EMD cluster (Cluster 1 n=18; Cluster 2 n=6; Cluster 4 n=26; Cluster 5 n=7). (All) Median and 95% CI shown.Extended Data Fig. 7 |.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 8 |.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 9 |.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Median and 95% CI shown.Extended Data Fig. 10 |.",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  }
]